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THE ROLE OF ADAM10, ADAM17, AND SPAG6 IN HUMORAL IMMUNITY AND
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ADAM10, ADAM17, and SPAG6 contribute significantly to humoral immunity and
secondary lymphoid tissue architecture. ADAM10 and ADAM17 are two closely related
zinc-metalloproteinases. Through cleavage of their ligands CD23 and TNF,
respectively, they greatly influence IgE production and secondary lymphoid tissue
architecture maintenance. Th1 prone WT strains initially exhibit increased ADAM17 and
TNF yet reduced ADAM10 relative to Th2 prone WT strains. In the absence of B cell
ADAM10, a compensatory increase in ADAM17 and TNF cleavage is noted only in Th1
prone C57Bl/6, not Th2 prone Balb/c. B cell TNF homeostasis is important for
maintaining secondary lymphoid tissue architecture. We show for the first time that

excessive B cell TNF production in C57-ADAM10B-/- lymph nodes contributes to loss of
B/T segregation, increased HEV number and size, fibrosis, loss of FDC networks, and
impaired germinal center formation. Furthermore, B cell ADAM10, which enhances IgE
production through CD23 cleavage, is shown to be a marker of Th2 susceptibility. B cell
ADAM10 is elevated in Th2 prone mouse strains and allergic patients compared to Th1
prone controls and as B cell ADAM10 level increases, so does IgE production. Lastly,
the B cell profile of allergic patients is determined to be B cell
ADAM10highADAM17lowTNFlow.
Furthermore, the mechanism underlying reduced class-switched antibody
production in C57-ADAM10B-/- mice is explored. C57-ADAM10B-/- B cells exhibit a B10,
or IL-10 producing, phenotype, which is linked to reduced antibody production.
Furthermore, increased Tregs noted in C57-ADAM10B-/- mice contributed to reduced
class switched IgE production and disease parameters following a house dust mite
airway inflammation challenge.
SPAG6, a component of the central apparatus of the “9+2” axoneme, plays a
central role in flagellar stability and motility. Immune cells lack cilia, but the
immunological synapse is a surrogate cilium as it utilizes the same machinery as
ciliogenesis including the nucleation of microtubules at the centrosome. We
demonstrate that Spag6 localizes in the centrosome and is critical for centrosome
polarization at and actin clearance away from the synapse between CTL and target
cells. Furthermore, improper synapse formation and function likely explains reduced
CTL function and class-switched antibody production in Spag6KO mice.

Section 1: The role of B cell ADAM10, ADAM17, and TNF in secondary lymphoid
tissue archiecture and antibody responses.
Chapter 1: Introduction to ADAM10, ADAM17, and their respective ligands in
humoral immunity and secondary lymphoid tissue architecture
1.1.1 Introduction to ADAM10 and ADAM17
ADAMs Overview
A disintegrin and metalloproteinases (ADAMs) belong to the metzincin
superfamily of zinc dependent proteases and specifically to the M12B adamalysin
protease subfamily along with structurally related snake venom reprolysins (SVR) and
ADAM-thrombospondins (ADAMTS) [1,2]. All known ADAM proteins contain the
following structural domains starting at the N terminus: (1) A pro-domain, which
behaves as a chaperone for protein folding [3], and is thought to be cleaved
intracellularly by pro-protein convertases during Golgi transit [4]; (2) A zinc dependent
metalloprotease domain, which participates in substrate cleavage; (3) A 14 amino acid
disintegrin loop binding domain, which confers substrate specificity [5]; (4) A cysteine
rich ligand binding domain; (5) An EGF-like domain, which is absent in ADAM10 and
ADAM17; (6) A transmembrane domain, which differentiates ADAMs from other
metzincin family members; and (6) A cytoplasmic tail domain that varies widely in length
and sequence between ADAM members (Figure 1).
Unlike other metzincin family proteases such as SVR, ADAMTS, and matrix
metalloproteases (MMPs), ADAMs are unique in that they are catalytically active while
membrane bound. Because they are membrane bound, ADAMs mediate ectodomain
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shedding of mainly type 1 and type 2 transmembrane proteins. This ectodomain
shedding can lead to downregulation of signaling events and/or effect autocrine and
paracrine signaling through release of soluble mediators [6]. Furthermore, they
participate in regulated intramembrane proteolysis (RIP), which requires receptor-ligand
interaction [7]. ADAM-mediated proteolysis is both constitutive and inducible and can
be modulated by many factors including: intracellular calcium levels, membrane lipid
composition, ease of removal of the inhibitory pro-domain, and post-translational
modification of the cytoplasmic tail domain [8]. Lastly, the number and function of each
ADAM protein varies between species. For instance, the human genome contains 25
ADAM genes whereas the mouse has 37. Furthermore, which ADAMs are catalytically
active may vary between species and some ADAMs, specifically in humans, are thought
to play a role in protein folding rather than catalysis because the critical zinc binding
active site is absent [1]. Overall, catalytically active ADAMs, termed sheddases, share
the following zinc-binding consensus sequence: (HEXGHXXGXXHD)[9].
ADAM10
ADAM10 was initially characterized in 1996 through study of its homolog in
Drosophila, Kuzbanian (kuz). Studies of kuz deficient embryos revealed its critical
importance in the development of the peripheral and central nervous system (CNS) [10].
Cloning and sequencing of kuz demonstrated disintegrin and metalloprotease domains
homologous with bovine metalloprotease (BMP), which would later be called ADAM10
[10]. Subsequent studies regarding nervous system defects in the absence of ADAM10
revealed the key role of ADAM10 in Notch signaling [11]. Given the importance of
Notch in early development, ADAM10 deficient embryos experience early death at
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embryonic day 9.5 due to defects in CNS and cardiovascular development [12].
Therefore, conditional knockout models have typically been used to study ADAM10 in
vivo.
Regulation and trafficking of ADAM10 to its sites of action is still poorly
understood although some players have been identified. ADAM10 is ubiquitously
expressed and is synthesized in the endoplasmic reticulum (ER) in an inactive pro-form.
Tetraspanin 15 (TSPAN15) helps to accelerate ER exit to the Golgi [13]. Tetraspanins
are termed “molecular facilitators” or chaperones that modulate the formation and
stabilization of signaling complexes [14,15]. During Golgi transit, furin and pro-protein
convertase (PC7) remove the inhibitory, pro-domain from ADAM10 [16]. TSPAN15
remains with ADAM10 throughout this process and helps with the integration and
stabilization of ADAM10 into the membrane and further helps ADAM10 gain access to
substrates. Furthermore, ADAM10 is known to bind TSPAN12, which has been shown
to aid in ADAM10 maturation. siRNA ablation of TSPAN12 reduced ADAM10
maturation and its shedding of amyloid precursor protein (APP) [17]. While it is well
known ADAM10 cleaves membrane bound substrates from the plasma membrane,
there is also evidence that ADAM10 cleaves in the endosomal pathway and is more
catalytically active at acidic pH [18]. Following internalization of ADAM10 and its
substrate, they are trafficked through the endosome into multivesicular bodies where
shedding occurs and both are then sorted into exosomes [19]. Exosomes are 30100nm, membrane-containing vesicles that are released from cells, express MHC and
integrins, and may be able to present antigen to T cells [19,20]. Furthermore, Tousseyn
et al. showed that ADAM10 itself can be processed by ADAM9, ADAM15, and γ-
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secretase, releasing the ADAM10 intracellular domain, which can modulate gene
transcription [21]. One direct consequence of ADAM10 processing was described by
Arima et al. in human prostate cancer progression. ADAM10 translocation to the
nucleus occurred more frequently in prostate cancer cells compared to benign prostatic
hyperplasia (BPH), which expressed predominantly membrane ADAM10 [22].
Little is known about ADAM10 regulation following pro-domain cleavage.
Following ADAM10 activation, in vitro ADAM10 activity can be inhibited by tissue
inhibitors of metalloproteases (TIMP)-1 and TIMP-3 [23]. Additionally, its proteolytic
activity is enhanced by calcium influx, retinoic acid receptor signaling, PKC signaling,
cholesterol depletion, kainite receptor signaling and N-glycosylation [24–29].
Regulation of ADAM10 activity is critical for maintaining a homeostatic release of
substrates. A critical ADAM10 substrate for both organ system development as well as
lymphocyte development is Notch receptor(s). While ADAM10 has many substrates
several important ones for this discussion will be CD23 and TNF. The low affinity IgE
receptor, CD23, regulates IgE production [30]; and, TNF is a pro-inflammatory cytokine
that is also important for maintaining secondary lymphoid tissue architecture (section
1.1.6) [31–34]. Lastly, ADAM10 participates predominately in cis-cleavage but has
been shown in certain instances to cleave substrates in trans [35].
ADAM17
TNF is a key pro-inflammatory cytokine, which exists as a 26kDa transmembrane
protein (mTNF) and a 17kDa soluble molecule (sTNF) [36]. Given its critical
importance, many groups aimed to discover the protease responsible for its cleavage.
In 1997, two groups simultaneously described a new ADAM protease, ADAM17, which
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was responsible for the cleavage of pro-TNF [37,38]. Its gene is located on
chromosome 2p25 in humans and chromosome 12 in mice. Similar to ADAM10, it is
ubiquitously expressed in many cells and tissues and is critical during development [37].
Although ADAM17 is most closely related in structure to ADAM10, as both lack the
EGF-like domain found in other ADAMs, they still only share 30% homology [39].
Data on the overall regulation and trafficking of ADAM17 is sparse and often
contradictory. ADAM17 has an inhibitory pro-domain that is cleaved similar to ADAM10
by furin in the trans-Golgi network [40]. While pro-domain removal is critical for
enzymatic activity, it is not required for ADAM17 transport to the plasma membrane
[41]. Furthermore, immunohistochemistry evidence suggests that active ADAM17
exists in the perinuclear region with very little on the plasma membrane [40], but many
still believe cleavage is mostly restricted to the plasma membrane. Whereas
tetraspanins are important for ADAM10 trafficking through the ER and Golgi, it is a
rhomboid protein, iRhom2, which is critical for ADAM17 trafficking [42,43]. iRhom2
escorts ADAM17 from the ER, through the trans-Golgi network, and ultimately to the
site of ligand cleavage. In the absence of iRhom2, furin-mediated proteolysis of
ADAM17 and trafficking to the cell surface does not occur [42,43]. Post-translational
modifications of ADAM17 protein include phosphorylation of ADAM17 residues,
specifically serine and threonine. Currently, there is conflicting evidence about which
residues are critical for ADAM17’s activity and whether phosphorylation or dephosphorylation of those residues enhance activity. One example is ADAM17
modification following phorbol ester (PMA) stimulation. PMA is known to stimulate
ADAM17 activity through phosphorylation events, but conflicting reports have named
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both threonine 735 and serine 819 as the critical phosphorylation site [44,45]. In
general, however, it is accepted that various stimuli may cause a differential
phosphorylation or de-phosphorylation pattern but exact mechanisms are unknown.
Lastly, ADAM17 activity is inhibited endogenously by TIMP-3 and has been shown to
have several other binding partners, including α5β1 integrin, whose roles in modulating
ADAM17 activity are still under investigation [39].
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Figure 1. Schematic of ADAM10 and ADAM17.
ADAM10 and ADAM17 are membrane bound proteases and are composed of the
following domains: (1) zinc dependent metalloproteinase (yellow); (2) disintegrin (red);
(3) cysteine-rich (green);; (4) transmembrane (orange);; (5) short cytoplasmic tail (black).
ADAM10 and 17 mediate cleavage of cytokine
cytokines and growth factors as well as initiate
signaling events through receptor cleavage.
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1.1.2 Introduction to secondary lymphoid tissues
Secondary lymphoid tissues are primary sites of adaptive immune responses and
consist of lymph nodes (LN), spleen, tonsils, Peyer’s patches (PP), bronchiolarassociated lymphoid tissues (BALT), gut-associated lymphoid tissues (GALT), and
mucosa-associated lymphoid tissues (MALT). They are located strategically throughout
the body in order to efficiently alert immune cells to the presence of foreign antigen and
allow a structured framework for their encounter [46–49]. While lymphocytes and other
immune cells are mobile and migrate in and out of secondary lymphoid tissues, their
architecture is tightly regulated and organized. During embryogenesis, secondary
lymphoid tissues begin to develop when hematopoietic lymphoid tissue inducer cells
(LTi), expressing lymphotoxin αβ (LT), and mesenchymal cells, expressing LTβ
receptor, interact. Induction of LT signaling in mesenchymal cells triggers their
differentiation into stromal organizer cells and induces homeostatic chemokine
expression, such as CXCL13, CCL19, and CCL21, that aid in migration of naïve
lymphocytes [47,50,51]. The critical importance of LT is demonstrated in LT-deficient
mice, which lack peripheral LN, PP, and demonstrate severely disrupted splenic
architecture.
Secondary lymphoid tissues are highly organized tissues, which is thought to aid
in efficient response to foreign antigen. LNs, for instance, have an afferent vasculature
supply, which brings antigen presenting cells (APCs) and foreign antigen into the LN
marginal sinus. Lymphocytes and APCs can also access the LN through high
endothelial venules (HEVs) found in the paracortex. The LN is divided into a cortex and
medulla. The cortical region consists of (1) the outer cortex, or B cell zone, which
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contains resting, primary B cell follicles; and, (2) the paracortex, where T cells reside.
The medulla is divided into medullary chords containing macrophages and plasma cells
and medullary sinuses, which drain immune cells into efferent lymphatics. Splenic
structure, while reminiscent of LN structure, varies in several ways [47,51]. The spleen
is divided into red and white pulp. The red pulp is responsible for the filtration of red
blood cells (RBCs) and removal of damaged or aged RBCs from circulation [47]. The
white pulp consists of periarteriolar lymphoid sheaths (PALS), which are comprised of a
central arteriole surrounded by a T cell rich compartment encircled by B cell follicles
containing FDCs [47,49]. The red and white pulp is separated by the marginal zone
(MZ), which holds MZ macrophages and MZ B cells (MZB). MZB development and
maintenance requires CD19, Notch2, and ADAM10 protein expression and signaling
[52–54]. Briefly, B cell specific Notch2-/- mice fail to develop MZB as do B cell specific
ADAM10 deficient mice.
B and T cells home to their respective zones due to chemokine gradients. B
cells express CXCR5, which binds CXCL13 causing migration to the follicle. It is
thought that follicular dendritic cells (FDCs), which reside in the B cell follicle, release
CXCL13 [55]. B cells typically enter the LN through HEVs located in the T cell zone
before migrating to the B cell follicle; however, they may also enter through the afferent
lymphatic system. Fibroblastic reticular cells (FRC) reside in the T cell zone and
release CCL19 and CCL20, which bind CCR7 on naïve T cells and dendritic cells (DC)
[56]. Thus, CCL19/20 interaction with CCR7 is important for both T cell homing to the
paracortex as well as DC migration to lymphoid tissues. When dendritic cells encounter
antigen in the periphery, the antigen is processed and presented in major
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histocompatibility complex class II (MHCII) and co-stimulatory molecules, CD80/86, are
upregulated. When the DC enters the paracortex, MHCII plus antigen is recognized by
the TCR on antigen-specific CD4+ T cells and CD80/86 interacts with T cell CD28 to
provide the second signal for activation. Furthermore, the cytokine environment will
cause CD4+ T cell differentiation into various T helper (Th) cell classes (see section
1.1.5) [57,58].
1.1.3 B cell activation
B cells are responsible for the humoral arm of the adaptive immune system and
produce high affinity antibody against foreign antigens. B cells initially express
membrane bound immunoglobulin, also known as the B cell receptor (BCR), which
confers specificity to a particular antigen. The BCR complex is comprised of cell
surface immunoglobulin made of a heavy and light chain as well as antigen-nonspecific,
invariant proteins Igα and Igβ, which express immunoreceptor tyrosine-based activation
motifs (ITAMs) [59,60]. Activation of B cells requires cross-linking of the BCR, thus
complex, multivalent antigens are stronger B cell activators because they allow
extensive receptor crosslinking. Following crosslinking, ITAMs are phosphorylated by
Src family tyrosine kinases (Lyn, Fyn, and Blk) followed by activation of Syk tyrosine
kinase. Syk then phosphorylates its targets including BLNK, CD19, and PLC-γ, which
activates Ca2+ and MAP kinase signaling. Ultimately, NFκB, NFAT, and AP-1
transcription factors are activated and lead to downstream activation of genes required
for B cell proliferation and differentiation. BCR signaling is further modulated by a B cell
co-receptor complex comprised of CD21, CD19, and CD81 [59–61]. In addition to
antigen induced signaling through the BCR, B cells process and present antigen in
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MHCII for CD4+ T cell recognition and receive cytokine signals that further affect their
activation.
T dependent responses
Protein antigens are considered T cell or thymus dependent (TD) antigens as B
cells require T cell help for activation. Antigen-bound B cells encounter T cells at the TB border in secondary lymphoid tissues. A cognate interaction between antigen-specific
B and T cells occurs as B cells process and present antigen in MHCII to CD4+ T helper
cells. Additionally, CD40 receptor on B cells engages CD40 ligand (CD40L) on T cells
and T cells deliver cytokines signals such as IL-4, IL-5, IL-6, and IL-21, which help
shape humoral responses. Following this cognate interaction, B cells proliferate or
clonally expand in a primary, extra-follicular focus at the T-B border and form antibodysynthesizing plasmablasts, which have both membrane bound and secretory antibody
(Ig). At this point, B cells commit to an extra-follicular or germinal center (GC) pathway.
It is not clear what causes commitment to either pathway. Paus et al. proposed that B
cells with highest antigen affinity initially will differentiate along the extra-follicular
pathway into plasma cells [62]. These extra-follicular origin plasma cells tend to be
short-lived, non-migratory, and primarily secrete IgM [63,64]. The germinal center
pathway is discussed in section 1.1.4.
T independent responses
B cell responses to T-independent (TI) antigens do not require T cell help and is
why antibody responses exist in humans and mice with T cell deficiencies. TI antigens
are subdivided into TI type 1 (TI-1) and TI type 2 (TI-2) antigens [65]. TI-1 antigens,
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also called B cell mitogens, can activate immature or mature B cells and intrinsically
induce B cell division. They typically cause polyclonal B cell activation, especially at
high concentration. A classic TI-1 antigen is lipopolysaccharide (LPS) [66]. TI-2
antigens can only activate mature B cells to make IgM and are thought to do so by
cross-linking many BCRs on mature, antigen-specific B cells. B cells responding to TI-2
antigens further require a cytokine signal called B cell activating factor (BAFF) in order
to induce class-switching to IgG [67,68]. TI-2 antigens are highly repetitive
polysaccharides and help confer immunity to encapsulated bacteria [65]. B1b B cells
(B220+CD23-CD11b+CD5+) and MZB are thought to make antibody by this mechanism
[69]. In general, both TI-1 and TI-2 antigens are thought to be poor at generating B cell
memory responses; but; it has been reported that LPS and polysaccharide antigens can
induce a memory response in rats [66].
1.1.4 Germinal Centers
Structure, formation, and maintenance
Once B cells are activated at the T-B border, some will migrate to the follicle via
CXCL13/CXCR5 interactions and form a germinal center (GC) [55,57]. A GC is a
specialized microenvironment within the follicle where B cells rapidly divide and undergo
class switch recombination, somatic hypermutation, and affinity maturation to
strengthen antibody binding. The GC can be divided into the mantle zone, dark zone
and light zone [57,58]. The mantle zone includes resting B cells that are pushed to the
periphery by the rapidly proliferating B cell population as well as recirculating B cells.
The dark zone consists of rapidly dividing B cells, or centroblasts, that undergo somatic

12

hypermutation and class switch recombination [70]. The light zone contains FDCs, T
follicular helper cells (Tfh), and B cells (centrocytes) undergoing affinity maturation
[58,71]. B cells can proliferate albeit to a lesser extent in the light zone; but, this is
considered a site of massive apoptosis for B cells that lose antigen specificity.
Furthermore, while B cells classically move from dark to light zone, they can also move
from light to dark [72]. GCs are present for 3-4 weeks after antigen exposure with their
peak response occurring around day 15.
Other factors that are critical for GC formation and maintenance are Bcl6 and IL21 [73–76]. Bcl6 is a transcriptional repressor found in both B cells and Tfh cells [73–
75]. Bcl6 is required to prevent apoptosis induced by DNA damage that occurs during
somatic hypermutation and class switch recombination [77]. Furthermore, Bcl6 is
thought to prevent differentiation of B cells into plasma cells until sufficient antibody
affinity is achieved [78]. Within the germinal center activated FDC produce IL-6, which
is known to induce Bcl-6 expression [79,80]. Lastly, IL-21 is known to play a critical role
in GC formation and antibody responses as IL-21 or IL-21 receptor deficient mice
exhibit significantly reduced antigen-specific IgG [81] and decreased GC persistence
[76]. IL-21 is not required, however, for memory B cell formation [76]. IL-21 induces
STAT3 signaling, which is essential for generation of IgG1 secreting cells [82].
Lastly, sphingosine 1-phosphate receptor 2 (S1P2) is critical for homing and
retention of cells in the germinal center. First, B cells require S1P2 to stay within the GC
niche [83]. Furthermore, Moriyama et al. described that Tfh cells within the GC express
high levels of S1P2 [84]. S1P2 deficient mice had reduced Tfh retention in GCs and it is
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thought that S1P2 and CXCR5 work cooperatively to traffic Tfh cells and retain them in
the GC [84].
Somatic hypermutation and class switch recombination
Both somatic hypermutation (SHM) and class switch recombination (CSR) occur
within the dark zone of the GC. The overall goal of SHM is to introduce mutations into V
regions of the immunoglobulin gene in the hopes to increasing antibody specificity.
While antigen specificity is not altered during class switch recombination, the class of
antibody (e.g. IgM, IgG) changes, which determines its function as well its distribution
throughout the body. Activation-induced cytidine deaminase (AID) is expressed only in
B cells and drives both SHM and CSR [71]. AID deaminates cytidine to form uridine in
switch regions of the immunoglobulin gene. This event triggers recruitment of base
excision repair machinery (BER) including uracil-DNA glycosylase (UNG), which
removes uridine. These mutations alter the amino acid sequence and may (1) disrupt
antibody structure; (2) cause reduction or loss of antibody specificity; or (3) improve
antibody specificity [65,71]. Because SHM can increase antibody specificity, it is said to
drive affinity maturation. After AID and UNG steps, CSR further requires
apurinic/apyrimidinic site endonuclease 1 (APE1) to introduce single strand nicks on
both DNA strands, which leads to staggered double strand nicks. Double strand break
repair machinery (DSBR) is then recruited and removes the damaged DNA region,
ultimately driving recombination of the VDJ with a C region (e.g. Cµ, Cγ1, Cε), which
determines the isotype [85].
Affinity maturation and high affinity B cell selection
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B cell selection contributing to affinity maturation is still a very controversial topic.
Many mechanisms have been proposed for B cell selection post GC including (1)
competition for FDC bound antigen; and, (2) competition for Tfh help [86]. The ultimate
goal of B cell selection is to purge the germinal center of low affinity B cells and only
allow B cells with high affinity Ig to survive. In the classical model, B cells compete for
binding to FDC, which have retained antigen. B cell fate is dependent on the strength of
interactions with the antigen. If BCR signaling is too weak, apoptosis occurs [87]. If
BCR signaling is sufficient, the B cell survives and presents antigen to Tfh cells, which
stimulate B cell differentiation into plasma cells or memory B cells. Critics of this theory
state that this theory alone does not account for the robustness of affinity maturation
that is observed [88]. An alternate theory states that Tfh cells do not only provide
differentiation signals at the end but also play an important role in the selection process
[57,88]. While the topic is still controversial, high affinity B cells ultimately leave the GC
following selection and differentiate into plasma cells or memory B cells.
1.1.5 Th differentiation and associated antibodies
When naïve CD4+ T cells leave the thymus, they are capable of differentiating
into several different Th subtypes depending on the cytokine environment, the antigen
to which the immune system is responding, and cell signaling events that upregulate
transcription factors characteristic of a particular subtype [89]. For the purposes of work
described herein, Th1 and Th2 differentiation are highlighted.
Th1 differentiation occurs during infection with intracellular pathogens and when
activated inappropriately, can result in autoimmunity. IFNγ and IL-27 (IL-12 family
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cytokine) initiate STAT1 and STAT1/4 signaling, respectively, leading to T-bet (Th1
transcription factor) upregulation, which together with Runx3 increases transcription of
more IFNγ [90]. Furthermore, T-bet and Runx3 silence the IL-4 gene and GATA3, thus
inhibiting Th2 differentiation [89]. IgG2a/c and IgG2b are considered “Th1” isotypes and
are increased by Th1 promoting cytokines such as IFNγ and IL-12 [91,92]. Th2 cells
respond to extracellular parasite infection and are required for the induction and
persistence of asthma and allergy [93,94]. Th2 differentiation requires IL-4 and IL-2
signaling. IL-4 induces STAT6, which drives GATA3 transcription factor expression.
GATA3 has three critical actions. First, it suppresses Th1 differentiation by
downregulating STAT4. Second, it enhances Th2 cytokine production (e.g. IL4, IL5,
IL9, IL13, IL10, IL25). Third, it aids in the proliferation of Th2 cells [95,96]. IL-2 activates
STAT5. STAT5 and GATA3 bind different sites of the IL-4 gene and their coordinated
activity is required for IL-4 production [97]. IgG1 and IgE are considered “Th2” isotypes
as they are increased by Th2 cytokines such as IL-4 [91–93].
The Th1/Th2 paradigm is classically attributed to differences in CD4+ T cell
response, with B cells considered bystanders waiting for the T cell cytokine signal.
Allergic diseases, such as asthma and allergic rhinitis, are skewed towards a Th2
phenotype whereas rheumatoid arthritis and other autoimmune disease are skewed
toward Th1 [98]. Furthermore, different mouse strains are considered Th1 or Th2-prone
based on their propensity to make “Th1” or “Th2” classes of antibody post immunization.
Classic Th1 (such as C57Bl/6 and SJL/J) and Th2-prone (such as Balb/c and A/J)
strains were characterized as high (Balb/c, A/J), intermediate (C57Bl/6), and low (SJL/J)
IgE responders following immunization [99]. Differences in their antibody production
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were attributed to differences in CD4+ T cell signal. Whether B cells from Th1 or Th2biased mouse strains have intrinsic differences that may affect IgE production, such as
varied ADAM10 and ADAM17 levels, has never been elucidated and is discussed
herein.
1.1.6 ADAMs 10 and 17 ligands in maintaining secondary lymphoid tissue
architecture and humoral responses
TNF Family Cytokines
TNF and its closely related family members, lymphotoxin alpha (LTα) and beta
(LTβ), have been extensively studied in the development and maintenance of
secondary lymphoid tissue architecture. Lymphotoxin is a trimeric cytokine and typically
exists as a secreted homotrimer, LTα3, or a membrane bound heterotrimer, LTα1β2, on
activated B, T, and NK cells [100]. LTα deficient mice lack lymph nodes and Peyer’s
patches and exhibit abnormal splenic architecture including loss of B cell/T cell
segregation and a complete absence of FDC networks, germinal centers, and MZB
[101,102]. LTα as a soluble homotrimer (LTα3) is also known to play an integral role in
lymphoid organization including B cell/T cell segregation by binding to the TNF receptor,
p55TNFR-1 [103]. LTβ deficient mice, however, experience more mild disruption as
they retain mesenteric and cervical lymph node development and maintain B cell/T cell
segregation, FDC networks, and germinal center formation in spleen [104]. There is
currently only one report that states that membrane bound LTα1β2 heterotrimer on T
cells is cleaved by ADAM17 in vitro and this cleavage is blocked by the ADAM17
inhibitor, TAPI-1[100]. They specifically were looking for a mechanism underlying
increased LTα1β2 in the serum and synovial fluid of rheumatoid arthritis patients [100].
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To date, there are no studies analyzing the relationship between ADAM17 and LTα1β2
in maintaining secondary lymphoid tissue architecture.
ADAM10 and ADAM17 are closely related ADAMs; therefore, many questions
have been raised about their functional redundancy under physiologic conditions as well
as in various genetically manipulated animal models. While ADAM17 is the principle
sheddase of TNF under physiologic conditions, ADAM10 is known to cleave TNF,
especially in the absence of ADAM17 [105]. Mezyk-Kopec et al. further demonstrated
that in ADAM17 deficient mouse embryonic fibroblasts, ADAM10 increases and
ADAM10 dependent cleavage of TNF is seen [106]. With regards to TNF and
secondary lymphoid tissue architecture, global TNF deficient mice exhibit disorganized
follicular dendritic cell (FDC) networks, aberrant germinal centers, and lack of splenic B
cell follicles [32]. Furthermore, in a B cell specific mutant model, which expresses a
non-cleavable form of mTNF, abnormal B cell/T cell localization with loss of a proper
cortico-medullary junction, reduced germinal center formation, impaired FDC network
development, and reduced IgG production against T dependent antigens was seen [34].
Thus, adequate levels of B cell produced sTNF is critical for maintaining secondary
architecture in the lymph node, spleen and Peyer’s patches and for optimal antibody
responses [34]. Interestingly, B cell specific ADAM10 deficient mice exhibit similar
alterations in immunized and naïve lymph nodes [31,107], which is described herein.
While lack of B cell sTNF is known to lead to phenotypic alterations, work herein
demonstrated for the first time that excessive B cell sTNF also leads to defects in
secondary lymphoid tissue architecture.
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Lastly, B cell TNF production can affect downstream antibody production. First,
given that proper secondary lymphoid tissue architecture is critical for optimal germinal
center formation and antibody production, B cell TNF homeostasis is critical for proper
antibody responses [32–34]. Furthermore, Frasca et al. demonstrated that increased B
cell TNF production is a key factor implicated in B cell aging, which ultimately curtails
class-switched antibody production [108]. Therefore, both excessive and too little B cell
TNF has negative consequences on optimal antibody production.
ICOSL
ICOS is inducible costimulator molecule, which is a member of the CD28/CTLA4/B7 immunoglobulin superfamily. It is found on activated T cells and binds ICOSL,
which is found on B cells, DCs, as well as non-immune cells [109]. While not classically
discussed as a co-stimulation signal needed for B cell activation, it is known that ICOS/- [110] and ICOSL-/- [111] mice have defects in germinal center formation and antigenspecific antibody production. Marczynska et al. demonstrated that ADAM17 regulates
ICOSL cleavage in vitro [112]. Treatment of WT B cells with PMA resulted in cleavage
of ICOSL. B cells with significantly reduced ADAM17 expression (ADAM17ex/ex B cells),
however, exhibited reduced ICOSL cleavage following PMA stimulation [112]. To
determine if ADAM17 directly cleaved ICOSL, they performed purified recombinant
enzyme studies and found that ADAM17 does not directly cleave ICOSL, but instead is
indirectly involved in the downregulation of surface ICOSL [112]. Following in vivo
immunization, furthermore, ADAM17ex/ex mice have increased germinal center B cells
and plasma cells in draining LN, increased total and antigen specific IgG1 and IgG2a,
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and draining LN hyperplasia with normal architecture [112]. Therefore, decreased
ADAM17 and increased surface bound ICOSL lends to increased antibody production.
Furthermore, ICOS-ICOSL interactions are critical for the generation and
maintenance of T regulatory cells (described in 1.1.7). Zheng et al. noted that blockade
of ICOS-ICOSL interactions in vitro impaired Treg induction as well as expression of
CTLA-4 and other mechanisms characteristic of Treg suppression [113]. Furthermore,
Redpath et al. described that ICOS deficiency led to FoxP3+ Treg apoptosis, impaired
IL-10 production, and increased Th2 responses in the intestine during helminth infection
[114]. It is not clear, however, if ICOSL must be membrane-bound or soluble to induce
Tregs through ICOS receptor. Overall, given the importance of ADAM17 in regulating
ICOSL levels, ADAM17 may indirectly affect Treg induction and function by controlling
ICOSL levels. Specifically, increased B cell ADAM17 would lead to increased soluble
ICOSL, which may cause increased Treg induction through binding to ICOS receptor.
CD23, IgE, and asthma
CD23 is a unique Fc receptor as it is a type 2 transmembrane protein and a
member of the calcium dependent (C type) lectin family. It exists in two isoforms,
CD23a and CD23b, and has three domains: (1) IgE interacting carboxy terminal
domain, (2) stalk regions, and (3) a short cytoplasmic tail [115]. Surface CD23 levels
can be increased in an IL-4 or IL-13 dependent manner [115]. In humans, peripheral
blood mononuclear cells stimulated with IL-4 exhibit increased CD23 shedding and IgE
production whereas treatment with anti-CD23, which prevents its cleavage, inhibits IgE
production [116]. Several enzymes had been implicated in the cleavage of CD23
including ADAM8 [117] and other hydroxymate sensitive metalloproteinases [118], but
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ADAM10 was determined by Weskamp et al. in a series of loss and gain of ADAM
protease function experiments to be the principle sheddase of CD23 in B cells [30].
Once cleaved from the surface, sCD23 enhances IgE production by an unknown
mechanism. Several models exist that attempt to explain this relationship including: (1)
High levels of IgE stabilize mCD23 and reduce further IgE production while allergen
proteases and anti-CD23 stalk monoclonal antibodies destabilize CD23, increase its
proteolysis, and increase IgE production [115]; and, (2) sCD23 crosslinks membrane
IgE and CD21 resulting in increased IgE production [119]. This relationship between
ADAM10, CD23, and IgE has since ignited much interest in the asthma and allergy
fields regarding the use of ADAM10 or CD23 cleavage inhibitors as a mechanism to
prevent IgE synthesis.
Asthma is a chronic airway disease characterized by wheezing, cough, shortness
of breath, chest tightness, and “asthma attacks” caused by obstruction in airflow. In the
United States, prevalence has increased since 2001 with children and African
Americans having the highest incidence [120]. Unfortunately, this report did not
distinguish between the incidence in allergic and non-allergic asthma. Another
community based clinical study of Danish adolescents and adults, reported that allergic
asthma represents three out of five asthma cases. Furthermore, they reported that
allergic asthma patients had greater AHR compared to non-allergic asthma patients
[121]. Allergy and allergic asthma are considered classic Th2 diseases with IgE as the
predominant antibody class coordinating the response. IgE levels are tightly regulated
and of all Ig classes have the lowest levels in vivo [122]. Interestingly, IgE can detect
very low levels of antigen and is often the first to detect foreign particles in areas of
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interface with the environment. When these foreign particles are innocuous, such as
pollen, cat dander or peanut proteins, IgE moves from beneficial to potentially life
threatening. IgE mediates allergic responses from mild to severe reactions, such as
allergic rhinitis, atopic dermatitis, urticaria, asthma, and anaphylactic shock [123].
IgE participates in the immune response in one of three ways. First, antigen
specific IgE binds the high affinity IgE receptor, FcεRI, on mast cells (MCs) or basophils
where it can persist for up to 21 days waiting to bind to antigen, cross-link the FcεRI and
degranulate the MC [124,125]. Degranulation results in the release of many mediators
including (1) histamine, which increases vascular permeability and smooth muscle
contraction; (2) MC enzymes, such as tryptase and chymase, which cause connective
tissue and matrix remodeling; (3) cytokines, such as IL-4, IL-13, IL-5, and TNF, which
amplify the Th2 response, recruit eosinophils, and promote inflammation, respectively;
and (4) lipid mediators, such as leukotrienes, which increase vascular permeability,
stimulate mucus secretion, and cause smooth muscle contraction [126]. While
histamine, MC enzymes, and some TNF are stored as preformed mediators and
released immediately, the others are synthesized following IgE/ FcεRI cross-linking and
are important for the late-phase reaction [123,127]. Second, circulating IgE can bind to
its antigen creating an IgE-immune complex. IgE immune complexes are picked up by
circulating follicular (FO) B cells by binding to CD23, the low affinity IgE receptor
(FcεRII) [128]. These CD23+ B cells then traffic to the splenic follicles where antigen
transfer occurs followed by rapid increases in antigen-specific CD4+ T cell proliferation
and IgG responses [128,129]. Third, circulating IgE can bind to mCD23 on B cells and
shut down excessive IgE synthesis [115].
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1.1.7 T regulatory cells and their role in allergic airway disease
T regulatory cells (Tregs) are critical for maintaining peripheral tolerance,
immune homeostasis, and preventing autoimmunity. Furthermore, they are important
for suppressing allergy and asthma as well as inducing tolerance to dietary food
antigens and maintaining maternal tolerance to the fetus [130]. They are divided into
two sub-populations, natural Tregs (nTregs) and inducible Tregs (iTregs) [131]. nTregs
are derived centrally in the thymus through MHCII/TCR dependent interactions resulting
in high-avidity selection and express a T cell receptor (TCR) that has a diverse
repertoire for both self (although controversial) and foreign antigens [130,132].
Because self-reactive T cells are eliminated during negative selection, it has been
proposed that FoxP3+ T cells may resist negative selection [132]. Others believe,
however, that while a small subset of Tregs recognize self antigen weakly, this is “the
exception not the rule” [130]. Following differentiation in the thymus, nTregs migrate to
the periphery to prevent autoimmune reactions by raising the threshold of activation for
all immune responses and suppressing autoreactive T cells. nTregs require CD28 as a
costimulatory signal and IL-2 or IL-15 for activation [94]. iTregs, which have been more
recently defined, are generated in the periphery in secondary lymphoid or inflamed
tissues from CD4+FoxP3- T cells following TCR stimulation in the presence of TGFβ and
IL-2 leading to FoxP3 expression [94]. While not described herein, there are also 2
subclasses of FoxP3- iTregs that produce either IL-10 (Tr1 cells) or TGFβ (Th3 cells)
[94].
In mice, both nTreg and iTregs are defined by expression of the transcription
factor, forkhead box 3 (FoxP3) and express the following markers: CD4+CD25+FoxP3+
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[94,133]. The difference is that nTregs leave the thymus already expressing FoxP3
whereas FoxP3 expression is induced in iTregs following TCR engagement with TGFβ
and IL-2 signaling [94]. While the exact function of FoxP3 is unknown, genome analysis
found that it binds to about 1000 genes, some of which are important for TCR signaling,
and therefore may act as both a transcriptional activator and repressor [130]. Other
markers that are also characteristic of Treg cells include ICOS, PD-1, GITR, LAG3,
CTLA-4, neuropilin-1, and Helios. Huang et al. compared these surface markers on
iTregs and nTregs and found that iTregs had increased ICOS and CTLA-4 compared to
nTregs but equal levels of PD-1, GITR, LAG3, neuropilin-1 and reduced Helios [134]. A
different report, however, states that nTregs exhibit higher expression of PD-1,
neuropilin 1, and Helios compared with iTregs [135]. It is still difficult, therefore, to
differentiate between these two populations in vivo as there is still controversy over their
surface markers; and, a unique marker has not been discovered to differentiate
between the two groups.
Functionally, both nTregs and iTregs act synergistically to induce tolerance and
suppress immune cell proliferation and function. Bilate et al. proposed that the
collaboration between nTregs and iTregs is due to their non-overlapping TCR
repertoires [131]. Both are able to suppress (1) T cell proliferation in addition to other
immune cell types; (2) Tbet and GATA3 upregulation, (3) cytokine production; (4) CD8+
T cell cytotoxic activity; and (5) antibody production [136]. Suppression mechanisms
used include secretion of inhibitory cytokines (IL-10, TGFβ, and IL-35), competition for
growth factors such as IL-2, and CTLA-4 mediated downregulation of T cell responses
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[136]. However, the exact mechanisms by which nTregs and iTregs induce tolerance
are still under investigation.
Given that Tregs inhibit T cell proliferation, Th2 differentiation, Th2 cytokine
production, and antibody production, it is obvious that Tregs would be beneficial in
reducing or preventing induction of allergic diseases and asthma [136,137]. In a chronic
OVA-induced lung inflammation model, adoptive transfer of CD4+CD25+ Tregs after
airway disease was already established led to a reduction in eosinophils, Th2 cytokines,
peribronchiolar lung collagen, and mucus. Airway resistance (AHR) in this study,
however, was not affected by Treg transfer after disease was already established [138].
Other acute and chronic murine airway hypersensitivity studies, however, clearly
demonstrated that Tregs reduce AHR [139–141]. Furthermore, the presence of Tregs
appears to be protective in healthy individuals. Healthy children or those diagnosed
with chronic cough had increased CD4+CD25+ Tregs in BALF compared to children with
asthma [142]. With regards to B cell IgE production, Meiler et al. demonstrated that
Tregs exert their negative influence on allergy induction by suppressing IgE production
and instead inducing IgG4 class-switching [143]. Furthermore, Xu et al. [141] reported
that adoptive transfer of in vitro generated iTregs reduced OVA-specific IgE levels
following OVA sensitization and challenge. Overall, both nTregs and iTregs are thought
to cooperatively limit allergic disease induction by (1) suppression of eosinophil and
mast cell migration and activation, (2) isotype switching from IgE to IgG4, (3)
suppression of inflammatory cell migration into lung tissue, (4) reducing AHR, and (5)
suppressing Th2 differentiation and cytokine production (IL-4, IL-5, IL-13) [144].
1.1.8 B regulatory cells: A unique B cell subset
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Similar to T helper cell subsets, B cells can also be classified based on cytokines
they produce. A subset of B cells, termed B regulatory cells, dampen or suppress
immune responses [145–147] . Thomas Tedder, a pioneer in the B regulatory cell field,
initially described B regulatory cells as IL-10 producing B cells. However, in his recent
review, he acknowledges that IL-10 producing B cells (B10 cells) represent a specific
subset of B regulatory cells [148]. Mizoguchi et al. describes other mechanisms B
regulatory cells may use, in addition to IL-10 production, to mediate immunosuppression
including (1) TGFβ1 production, (2) IgG and IgA production to mediate neutralization of
harmful factors, and (3) induction of apoptosis in effector T cells [147]. Non-IL10
producing B regulatory subsets, however, are far less defined. B10 cells, specifically,
are known to suppress aspects of both the innate and adaptive immune response. B10
cells are defined functionally by intracellular IL-10 staining and unfortunately a unique
set of surface markers has not been identified [145,146]. In mice, they are known to
share overlapping markers with marginal zone B cells and B1 B cells including
CD1d+CD5+IgDloIgMhi but intracellular IL-10 staining is still required for identification
[145].
B10 cells develop from a B10 progenitor cell (B10pro) defined as CD1d-CD5MHCII+IgM+CD40+ and represent 1-2% of total splenic B cells [145,149]. The initiation
of IL-10 secretion by B10 cells requires several factors including BCR ligation with
antigen [150,151], CD40 ligation [152,153], and IL-21 signaling [154]. Interestingly, T
cells are not required for B10 development but cognate interactions are important for
eventual IL-10 secretion [154]. TLR-4 (LPS ligand) and TLR-9 (CpG oligonucleotide
ligand) signaling augments IL-10 secretion but is not essential for B10 development
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[151]. For instance, MyD88-/- mice have equal frequencies of B10pro and B10 cells
compared to WT but not optimal IL-10 expression [151].
Functionally, B10 cells suppress aspects of both innate and adaptive immunity
through IL-10 production [155]. IL-10 can suppress proinflammatory cytokine
production [155], MHCII and costimulatory molecule expression [156], T cell activation,
and antigen uptake by dendritic cells [157]. Currently, there is controversy over whether
or not B10 cells enhance Treg development and function. Various studies using an
experimental autoimmune encephalomyelitis (EAE) model to study multiple sclerosis
(MS) have concluded that IL-10 made by B10 cells was both involved [158] and not
involved [159,160] in Treg generation and function. However, another study concluded
that the supportive effect of B10 cells on Tregs in EAE is IL-10 independent and
therefore another regulatory mechanism may be involved [161]. It is known, however,
that CD19-deficient NZB/W mice, which have significantly reduced B10 cells, have
reduced Tregs. Furthermore, adoptive transfer of B10 cells into CD19-deficient NZB/W
mice induced Treg expansion [162]. With regards to murine models of airway
hypersensitivity, Amu et al. demonstrated that adoptive transfer of B10 cells induced
nTreg recruitment into lungs, which reduced airway inflammation [163]. Overall, many
studies have demonstrated a link between B10 cells and Treg expansion, but this
relationship needs to be further explored.
A central question regarding B10 function is whether B10 cells differentiate into
plasma cells and secrete antibody. Maseda et al. described B10 cells as transient IL-10
producing B cells of which a subset will become antibody secreting plasma cells [164].
Following IL-10 secretion, expression of blimp1 and irf4 transcription factors increases
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while bcl6 decreases, which is characteristic of plasma cell differentiation. Furthermore,
Maseda et al. found B10 derived IgM was reactive with both self and foreign antigen;
and, B10 cells made antigen specific IgG1 post immunization [164]. Therefore, B10
cells are a unique B cell subset of which some retain the ability to make antibody but
are by definition immunosuppressive in nature.
1.1.9 Section 1 aims
Overall, the aim of section 1 is first to define immune system characteristics of B
cell specific ADAM10 deficient mice on two backgrounds, Th1 prone C57Bl/6 and Th2
prone Balb/c. Specifically, the mechanisms underlying aberrant secondary tissue
architecture and defects in antigen-specific, class-switched antibody production are
revealed. Furthermore, the regulation of ADAM10, ADAM17, and TNF in Th1 and Th2
prone mouse strains and in humans is explored with an emphasis on how B cell
ADAM10 level affects susceptibility to Th2 diseases and IgE production potential.
Lastly, the benefit of ADAM10 inhibitor therapy and insight into its mechanism of action
in airway inflammation models is described.
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Chapter 2: Materials and Methods
1.2.1 Mice
C57Bl/6 ADAM10B−/− (CD19-cre+/-) mice (C57-ADAM10-/-) were generated as
previously described [52] (see section 1.3.1) and backcrossed to Balb/c (BalbADAM10B-/-) for 8 generations and compared to respective littermate controls (CD19cre-/-). TNF knockout (TNF-αKO) mice used for bone marrow reconstitution studies
were purchased from Jackson Laboratory (no. 005540, B6.129S-Tnf). B6-Ly5.2/Cr
(CD45.1) congenic mice were purchased from National Cancer Institute/National
Institutes of Health. For B cell reconstitution studies, C57Bl/6 B cell deficient mice
(B6.129S2-Ighmtm1cgn/J, Jackson 002288) were used. A/J, SJL/J, C57Bl/6, and
Balb/c WT were from Jackson Laboratories. Healthy male and female mice aged 6–12
weeks were used in all experimentation except bone marrow reconstitution where only
WT female mice ages 6–8 weeks were reconstituted with sex-matched bone marrow
cells. The Virginia Commonwealth University Institutional Animal Care and Use
Committee approved all animal care and experimental protocols. For experimentation,
mice were euthanized by isoflurane inhalation and cervical dislocation.
1.2.2 Cell Isolation
Tissue preparation
Single cell suspensions of spleen or peripheral lymph node was prepared by
disrupting tissue between frosted glass slides. For peritoneal lavage, 1 mL of 2%FBS in
PBS was injected into the peritoneal cavity and removed. Suspensions were filtered
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through 40-µm Nylon Mesh (Fisherbrand) and RBCs lysed with ACK Lysing Buffer
(Quality Biological).
Magnetic bead isolation
Specific cell isolation was performed with magnetic bead isolation (Militenyi
Biotec). Briefly, a single cell suspension was generated as described above. Cells were
washed and resuspended in MACS buffer (PBS pH 7.2, 0.5% BSA, and 2mM EDTA)
and incubated with the corresponding magnetic beads for 20 minutes on ice. Cells were
then washed and passed through a pre-washed magnetic column according to
manufacturer’s protocol (Miltenyi Biotec). For positive selection, LS columns were
used. Following addition of cells, columns were washed three times and then flushed
with MACS buffer to elute cells for experimentation. For negative selection, LS columns
were used as described previously but flow through from column was collected. For B
cell isolation, total B cells were isolated using B220+ positive selection or naïve B cells
were isolated by CD43 depletion (CD43- cells collected from flow through). For T
regulatory cell induction experiments, CD4+CD25- cells were isolated. First, total
splenocytes were incubated with CD25-PE for 10 minutes in the dark, washed,
incubated with anti-PE beads, and CD25 negative cells collected in flow through.
CD25- cells were then incubated with CD4 (L3T4) beads and positive selection
performed for CD4+CD25- T cells.
1.2.3 In vitro activation
B cells: Anti-CD40, IL-4, LPS
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B cells were grown in complete RPMI 1640 medium containing 10% heatinactivated (56°C, 30 min) FBS (Gemini Bio-Products, West Sacramento, CA), 2 mM Lglutamine, 50 µg/ml penicillin, 50 µg/ml streptomycin, 1 mM sodium pyruvate, 50 µM 2ME, 1× nonessential amino acids, and 20 mM HEPES buffer (all from Invitrogen,
Carlsbad, CA), and stimulated in vitro for 1, 3, or 5 d with 1000 U IL-4 (NIH) and either
50 µg/ml LPS (from Escherichia coli 0111:B4; Sigma) or 1.25 µg/ml purified anti-mouse
CD40 (no. 102902; Biolegend). Supernatants were harvested at day 1, 3, or 5 for
ELISA and cells analyzed by flow cytometry, western, and qPCR.
B cells: PMA
B220+ B cells were isolated from total splenocytes and were left untreated
(media alone) or were treated with 250ng/mL PMA (Sigma). Cells were grown in
complete RPMI at 37°C. Protocol adapted from [112].
In vitro generation of CD4+CD25+ T cells
Plates were coated with anti-CD3 (1µg/mL, Biolegend) for 2 hours at 37°C then washed
with PBS before plating. 1mL of 2 x 106 CD4+CD25- cells (isolation described above)
was resuspended in X-Vivo15 serum-free medium supplemented with 10% FBS
(Gemini Bio-Products, West Sacramento, CA) (without antibiotics) and added to antiCD3 coated plates. Immediately, in vitro stimulating condition was added with all groups
having anti-CD28 antibody (2 mg/mL, Biolegend) and IL-2 (100U/mL, Peprotech) in
supplemented X-Vivo15 media [165]. Groups included media alone (negative control),
rTGF-β1 (5 ng/mL) alone (positive control), and conditioned supernatants from 5 day
anti-CD40/IL-4 treated B cells (WT or ADAM10B-/-) with or without ICOSL neutralizing
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antibody (Biolegend, isotype control Rat IgG2a). All groups were cultured for 4 days.
Percent purity of CD4+CD25- cells was determined by flow cytometry before culture
(>97%). After 4 days, percent induction of FoxP3 expression in CD4+CD25+ cells was
determined by flow cytometry or qPCR.
1.2.4 [3H] thymidine Proliferation
B cell and T cell proliferation was assessed after 72 h of growth, and a 24-h
pulse of [3H]thymidine, 1 µCi/well (Perkin Elmer, Waltham, MA), was used. Plates were
then harvested using a Filtermate cell harvester onto UniFilter-96 GF/C microplates
(Perkin Elmer), dried overnight, and analyzed using a Topcount Plate Counter (Perkin
Elmer).
1.2.5 Immunization
NP-KLH
Mice pre-bled the day before immunization and were immunized in the footpad
(two ipsilateral paws) and/or intraperitoneal with 10 µg 4-hydroxy-3-nitrophenylacetyl
coupled to keyhole limpet hemocyanin at a ratio of 27:1 (NP27KLH or NP-KLH herein)
(Biosearch Technologies) in 4 mg alum. For footpad injections, mice were given 10µg
NP-KLH (1µg/mL stock) in 9µL of PBS and 15µL of alum for a total of 25µL per paw.
For intraperitoneal injections, mice were given 10µg of NP-KLH (1µg/mL stock) in 90µL
of PBS and 100µL of alum (4 mg) for a total of 200 µL per injection. Mice were bled at
day 7, 14, and/or 21 post immunization and serum used for ELISA.
1.2.6 ELISA
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Total antibody
ELISA plates were coated with 5µg/mL of goat-anti Ig (SouthernBiotech) in BBS
(0.15M sodium chloride, 0.01 M borate buffer, pH=8.5) and incubated at 37°C for an
hour or at 4°C overnight. Plates were then washed three times with ELISA wash (PBS
with 0.02% Tween20). Blocking solution (PBS with 0.02% Tween20 and 2% FBS) was
then added and incubated at 37°C for an hour or at 4°C overnight. Plates were then
washed three times with ELISA wash and samples were added, diluted in block. For
standard curve, normal mouse Ig (Southern Biotech) was used and incubated at 37°C
for an hour. Plates were washed three times with ELISA wash and incubated with goatanti Ig-AP diluted 1:400 in block (Southern Biotech) for 1 hour at 37°C. Plates were
washed five times and developed with phosphate tablets (Sigma-Aldrich) dissolved in
substrate buffer (0.1g MgCl2.6H20, 0.2 NaN3, 50mL diethanolamine, pH to 9.8 per
500mL). Absorbance at 405nm was measured.
NP-specific antibody
ELISA plates were coated with 15µg/mL NP4BSA (high affinity) or NP25BSA (low
affinity) in PBS for sample wells and with 5 µg/mL of goat-anti-Ig (Southern Biotech) in
BBS for standards. The remaining steps were carried out as described above in ‘total
antibody’ section.
TNF
Soluble TNF from B cell supernatants was determined by mouse quantitative
ELISA kit (88-7324-88; eBioscience) according to manufacturers’ protocol.
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HDM specific IgE
HDM specific IgE ELISA was performed as described [31,166]. Briefly, plates
were coated with 20µg/mL HDM extract in 50mM carbonate buffer, blocked with
SuperBlock (Thermo Scientific), detected using goat anti-mouse IgE (Abcam), followed
by addition of Streptavidin-HRP (Southern Biotechnologies), and color developed with
tetramethylbenzidine + substrate (BD Biosciences). Reaction was stopped with 1N
H2SO4 and absorbance read at 450nm.
MUC5AC
BALF supernatants were analyzed for MUC5AC protein by ELISA as described
[167]. Briefly, BALF was diluted and 75µL was incubated with 75µL carbonate buffer.
Samples were incubated overnight without a lid at 37°C then washed three times with
PBS. Plates were blocked, detected with anti-Muc5AC mouse monoclonal antibody
(Pierce, 1:100), followed by addition of goat anti-mouse IgG-HRP (Southern
Biotechnologies,1:10,000), developed with tetramethylbenzidine + substrate (BD
Biosciences), stopped with 1N H2SO4, and absorbance read at 450nm.
1.2.7 PCR and Quantitative PCR
PCR
For genotyping, DNA was isolated using Direct Tail PCR Solution as directed by
the manufacturer (Viagen). Mangomix (Bioline) was used for amplification of CD19 crelines, ADAM-10 floxed alleles, YFP-Rosa and ADAM17. Cycling conditions were as
follows, 95°C for 3 minutes then 35 cycles of 94°C for 1 minute, 55°C for 1 minute, 72°C
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for 2 minutes, and a final extension at 72°C for 10 minutes. Sequences of all primers
described above are listed in Table 1.
Quantitative PCR
Total RNA was extracted from naive and stimulated total B cells using TRIzol
reagent (Invitrogen) according to manufacturer’s protocol and RNA concentration
quantified by a ND-100 NanoDrop spectrophotometer. RNA (400 ng/µl) was reverse
transcribed using an iScript cDNA Synthesis Kit (Bio-Rad). Real-time quantitative PCR
(qPCR) was performed with a real-time PCR machine (iQ5; Bio-Rad Laboratories).
Primers and probes used for TaqMan qPCR assay (all from Applied Biosystems) are
listed in Table 1. Fold variation was determined using the ∆∆Ct method of analysis
[168].
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Table 1: PCR and qPCR primers and probes
PCR
5’>3’
A10Flox (75302-75324) Exon 9
GTTGGACATAACTTTGGATCTCC
A10Flox (75536-75516) Intron 9
CGTATCTCAAAACTACCCTCC
A10Flox (74490-74513) Intron 8
TGTGTGAATAGTGCAGTGAACGCC
A17Flox F
TCCCCCAGCTAGATTGTTTG
A17Flox R
AGGACCCAGGTTCAGTTCCT
CD19 sense
TCGCGATTATCTTCTATATCTTCAG
CD19 antisense
GCTCGACCAGTTTAGTTACCC
YFP1 (oMIR 316)
GGAGCGGGAGAAATGGATATG
YFP2 (oMIR 833)
AAAGTCGCTCTGAGTTGTTAT
YFP3 (Ro 4982)
AAGACCGCGAAGAGTTTGTC
TNF F1
TACACAGAAGTTCCCAAATG
TNF F2
TCCCTCTCATCAGTTCTATG
TNF R1
GAAATCTTACCTACGACGTG
TNF R2
AAGCATCTATGCACTTAGAC
PCR: For detecting CRE-mediated deletion of the STOP cassette at the
ROSA/EYFP locus
ROSA26 (3937-3958)
TGGAGGCAGGAAGCACTTGCTC
EYFP (29-8)
GTGAACAGCTCCTCGCCCTTGC
Quantitative PCR
All from Applied Biosystems
18s
Mm03928990
ADAM10
Mm00545742
ADAM17
Mm00456428
FoxP3
Mm00475162
GAPDH
Mm99999915
Matrix metalloproteinase 13 (MMP13)
Mm00439491
TNF-α
Mm00443258
TTP/Zfp36
Mm00457144
Human adam10
Hs00153853
Human adam17
Hs01041915
Human TNF
Hs01113624
Human GAPDH
Hs02758991
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1.2.8 Western
Protein lysates were made according to the manufacturer’s protocol using Cell
Lysis Buffer (no.9803; Cell Signaling). Equal amounts of protein determined by Bradford
Assay were loaded onto Novex NuPAGE 10% Bis-Tris gels (Invitrogen), run for 35 min
at 200 V at RT, transferred to nitrocellulose membrane at 90 V for 2 hours on ice, and
equal transfer verified by Ponceau S (Sigma) staining. Blots were blocked (PBS, 0.02%
Tween-20, 5% dry milk) for 1 hour at RT or overnight at 4°C. Blots were then washed 3
times for 10 minutes (PBS, 0.02% Tween-20). Primary antibodies listed in Table 2
were diluted in block and incubated overnight. Blots were again washed 3 times and
incubated with respective secondary antibodies or anti–β-actin peroxidase (Table 2) for
2 hours at RT. Plates were washed 3 times and signal detected with 1:1 mix of
SuperSignal West Pico Chemiluminescent Substrate (no. 34080; Thermo Scientific).
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Table 2: Western Antibodies
Name
anti–β-actin peroxidase
anti-ADAM17
Goat anti-rabbit IgG,
HRP conjugate
secondary

Source
Sigma
Abcam
Southern
Biotechnologies
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Catalog Number
A3854
2051
4030-05

Dilution
1:25,000
1:1,000
1:5,000

1.2.9 Flow cytometry and immunohistochemistry
For all flow staining procedures, cells were isolated as in 1.2.2.
Flow cytometry – Surface, total (intracellular and extracellular), and nuclear staining
0.5-3 x 106 cells were washed in FACS buffer (2% FBS in PBS), decanted, and
incubated on ice with 1-5µg of Fc block (2.4G2) for 10 minutes to prevent non-specific
staining. Subsequently, cells were surface stained by incubating 0.25-0.5µg of antimouse antibodies (Table 3) for 30 minutes on ice. Cells were then washed with FACS
buffer. If further performing total staining, cells were fixed (FCM Fixation Buffer, Santa
Cruz Biotechnology) at RT for ten minutes, washed, permeabilized for 10 minutes at
RT, washed, Fc-blocked for 10 minutes on ice, and stained for 30 minutes on ice with
anti-mouse or anti-human antibodies. For secondary staining, cells were washed with
FACS buffer after primary staining and then stained with secondary antibodies (Table
3). If performing nuclear staining, cells were fixed (Biolegend Nuclear Fixation Buffer)
for 20 minutes at RT, washed, permeabilized (Biolegend Nuclear Permeabilization
Buffer), Fc Blocked, and stained.
Flow cytometry - Tyramide Signal Amplification
0.5-3 x 106 cells were stained using tyramide signal amplification (TSA) Kit #26
with HRP streptavidin (no. T20936; Molecular Probes) and an anti-mouse B220
antibody (Table 3). Kit reagents were prepared according to manufacturer’s protocol,
and tyramide amplification using the “Peroxidase Labeling assay” was performed with
the following modifications: cells were incubated with blocking reagent (10 µg antimouse unlabeled CD16/32 [2.4G2]) for 15 min; stained with biotin anti-mouse TNF-α

39

primary Ab (Biolegend); and after tyramide labeling, cells were washed twice and
stained with anti-mouse B220 (see earlier) for 30 minutes.
Flow cytometry – ICOSL cleavage kinetics
B220+ B cells were stained at time 0 for baseline ICOSL expression following Fc
blocking with 10µg anti-mouse unlabeled CD16/32 [2.4G2] for 15 minutes. B cells
treated with PMA were cultured for 5, 10, 20, 30, 45, 60, or 120 minutes at 37°C. At
each time point, cells were blocked and then stained for biotin anti-mouse ICOSL
followed by PE-Strepavidin.
Flow Analysis
For analysis, all samples were washed and resuspended in 500µL PBS. Flow
cytometry analysis was performed using a Canto or Fortessa (BD Biosciences) using
DIVA software at the Flow Cytometry Core at Virginia Commonwealth University. Data
analysis was performed with FCS Express, v. 4.
Immunohistochemistry
Ten-micrometer-thick frozen sections were cut from the excised mouse LNs,
fixed in absolute acetone, air-dried, and blocked with serum-free protein block (X0909;
Dako). The sections were dual- and triple-labeled for FDCs (CD21/CD35), B cells
(CD45R/B220), high endothelial venules (HEVs; anti-mouse/human peripheral node
addressin), T cells (rat anti-mouse CD90.2/Thy-1.2-PE), collagen type 1, and TNF-α
(Table 3). Sections were mounted with antifade mounting medium, Vectashield (Vector
Laboratories), coverslipped, and examined with a Leica TCS-SP2 AOBS confocal laser-
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scanning microscope. Three lasers were used: argon (488 nm), HeNe (543 nm), and
HeNe (633 nm; far red emission is shown as pseudoblue). Parameters were adjusted to
scan at 1024 × 1024 pixel density and 8-bit pixel depth. Emissions were recorded in two
or three separate channels, and digital images were captured and processed with Leica
Confocal, LCS Lite software, and ImageJ for color separation and quantitative
assessment of immunohistochemistry.
Immunohistochemistry – Tyramide Signal Amplification
TNF labeling was enhanced using fluorescein-TSA (TSA Plus Fluorescein
System; NEL741001KT; Perkin Elmer). In brief, after quenching endogenous
peroxidase using 1% H2O2, anti–TNF-α Ig was applied for 2 h, washed, then HRPconjugated secondary Ig was added for 1 h. After washing, HRP was allowed to
catalyze the deposition of fluorescein-labeled tyramide for 10 min, then was washed,
mounted, and examined.
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Table 3. Flow Cytometry and Immunohistochemistry Antibodies
Name
Flow Cytometry
ADAM10
Anti-human ADAM10
Anti- mouse and human
ADAM17
B220/CD45R
CD4
CD25
FoxP3
TNF
DyLight-649 anti-rabbit
IgG (secondary for
ADAM17)
Mouse IgG2b
Rat IgG2a
Rabbit IgG
ICOSL
Streptavidin
IL-10
Anti-human CD19
Anti-human CD14
Anti-human CD3
Immunohistochemistry
CD21/CD35
CD45R/B220
CD90.2/Thy-1.2

Label

Source

Concentration
used

PE
FITC
Unconjugated

R&D
R&D
Abcam

N/A

APC, FITC, PE
PECy7
PE
Alexa 647
Biotin
APC

Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend

N/A
N/A
N/A
N/A
N/A
N/A

FITC
PE
Unconjugated
Biotin
PE
APC
PE
APC
PE

R&D
Biolegend
In house
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend

N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

PE
Alexa Fluor 647
PE

Biolegend
Biolegend
Southern
Biotechnologies
Abcam
Biolegend

5-10 µg/mL
5-10 µg/mL
5-10 µg/mL

Collagen Type 1
Unconjugated
Peripheral node
Unconjugated
addressin (antimouse/human)
TNF
TSA
Abcam
*All antibodies are anti-mouse unless otherwise specified.
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N/A

5-10 µg/mL
5-10 µg/mL

5-10 µg/mL

1.2.10 Bone marrow reconstitution
Bone marrow cells were isolated as previously described with the following
modifications [169]. In brief, two femurs and two tibias from each mouse (WT [CD45.2],
ADAM10B−/−[CD45.2], or TNF-αKO) were centrifuged, RBCs lysed with ACK Lysing
Buffer (Quality Biological), bone marrow cells counted, and 5 million cells were i.v.
injected. For 50/50 mixtures, such as ADAM10B−/− + TNFKO, 100 µl/2.5 million cells
from each were used to prepare the final injection mixture.
B6-Ly5.2/Cr (CD45.1) congenic mice from National Cancer Institute/National
Institutes of Health were pretreated 5 days before irradiation with 100mg/L
(concentration 0.01%) enrofloxacin (Baytril) in sterile water. CD45.1 mice were
anesthetized using a 100 µL i.p. injection of ketamine/xylazine in PBS at a dose of 80
and 8 mg/kg, respectively. This was followed by two doses of 550 cGy irradiation,
separated by a 2-hour rest period, using an MDS Nordion Gammacell 40 research
irradiator with a [137Cs] source. After irradiation, mice were reconstituted by i.v. injection
with the indicated bone marrow cells as described earlier. After 6 weeks of
reconstitution, mice were footpad immunized in two ipsilateral paws with 10 µg 4hydroxy-3-nitrophenylacetyl coupled to keyhole limpet hemocyanin at a ratio of 27:1
(Biosearch Technologies) in 4 mg alum. Draining and non-draining popliteal and axillary
LNs

were

dissected

at

14

days

post-immunization

and

analyzed

by

immunohistochemistry.
1.2.11 Human Studies
The Virginia Commonwealth University IRB approved all human studies. Sixteen
symptomatic allergic rhinitis patients and 16 controls were recruited for the study by Dr.
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Anne-Marie Irani at VCU. Inclusion criteria included active allergic rhinitis symptoms and
a documented positive skin test or ImmunoCAP to an antigen as consented in IRB
#00870. Peripheral blood mononuclear cells (PBMC) were isolated from peripheral
blood using Ficoll, stained, and remaining PBMC underwent CD19 B cell selection using
magnetic beads (Miltenyi Biotec). B cells were cultured for 2 days (or 5 days for CD23
ELISA) with 200 ng/mL human IL-21 (ATCC), 1 µg/mL anti-CD40 (Clone G28-5, ATCC),
and 10 ng/mL rhIL-4 (R&D). Stimulated B cells were harvested, stained for flow
cytometry, analyzed by qPCR, and sCD23 determined by ELISA [170].. HDM
Dermatophagoides pteronyssinus IgE was determined by ImmunoCAP (Phadia, 144107-01).
1.2.12 Murine HDM Studies
C57Bl/6 WT, C57-ADAM10B-/-, Balb/c WT, and Balb-ADAM10B-/- mice were
intranasally exposed to 25µL saline or 15µg/25µL HDM extract (Greer Laboratories) as
described in Figure 18 [171]. For Treg depletion studies, 0.5mg/mL anti-CD25
(BioXCell, PC-61.5.3), 0.5mg/mL COH2 (control rat IgG1), or PBS was given i.p. 3 days
before first intranasal immunization and again 3 days after the first intranasal
immunization. Bronchoconstriction was assessed using Flexivent (Scireq, Montreal,
QC, Canada) as previously described [167]. Airway resistance (Rrs or AHR) was
determined at increasing doses of methacholine (5, 10, 25 mg/ml) and presented as (1)
percent increase from PBS baseline or (2) resistance value for each dose shown.
Total BALF volume and cell count was assessed and total cell count normalized
to 100µL. BALF supernatants were analyzed for MUC5AC protein by ELISA as
described [167] (see Section 1.2.6).
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1.2.13 Murine Lung Histology
Five µm sections of formalin-fixed, paraffin-embedded murine lung tissue were
stained with hematoxylin and eosin (H&E) and Periodic acid-Schiff (PAS) (AML
Laboratories, Inc. Baltimore, MD) and photographed using Olympus-DP70 camera on
Olympus-BX41 microscope. Histopathologic evaluation of H&E stained lung sections
from at least 4 mice per group was performed by a pathologist in a blinded fashion
using a semi-quantitative scoring system on a Nikon Eclipse microscope.
Peribronchiolar and perivascular inflammatory cellular infiltration were scored separately
as follows: 0, no or occasional cells; 1, few or loosely arranged cells; 2, focal
involvement of lung parenchyma with majority of airways or vessels having rings (partial
or complete) of inflammatory cells one cell layer deep; 3, patchy involvement of lung
parenchyma with majority of airways or vessels having rings (partial or complete) of
inflammatory cells two to four cell layers deep; 4, extensive involvement of lung
parenchyma with majority of airways or vessels having rings (partial or complete) of
inflammatory cells more than four cell layers deep. Individual scores for peribronchiolar
and perivascular inflammation were added together for a total maximum score of 8.
1.2.14 BALF by flow cytometry
BALF cells were stained with APC-B220, APC-CD3, BV421-1A/1E, BV605-CD11c, and
PE-CCR3 (Biolegend) after FcR blockade with anti-mouse CD16/32 (2.4G2). Samples
were examined on a BD Fortessa and analyzed with FCS Express, v. 4. using the
gating strategy described [172].
1.2.15 Statistical Analysis
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Normal distribution of data sets was determined using the Shapiro-Wilk normality
test with SigmaPlot 12.5. Furthermore, the mean and medians were close for data sets
indicative of normal distribution. When dealing with two groups, p-values were
calculated using unpaired two-tailed Student’s t-tests in GraphPad Prism. In the case of
non-parametric populations, p-values were calculated using two-tailed Mann-Whitney
test. When more than two were compared, p-values were calculated using a one-way
analysis of variance (ANOVA) with a Tukey post-test. Error bars represent the standard
error of the mean (SEM), standard deviation, or 95% confidence interval between
samples. p<0.05 is considered significant.
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Chapter 3: Th1 vs. Th2 background does not affect antigen specific antibody
production following B cell ADAM10 deletion; however, Th context greatly affects
B cell ADAM17 and TNF regulation and thus secondary lymphoid tissue
architecture
1.3.1 Generation of B cell specific ADAM10 deficient mice on two backgrounds
Our lab previously generated a B cell specific ADAM10 deficient mouse model
(ADAM10B-/-) on both a C57Bl/6 and Balb/c background. C57Bl/6 ADAM10B-/- (C57ADAM10B-/-) mice were initially generated by crossing homozygous floxed ADAM10
(exon 9) mice with CD19-cre knockin mice [52]. Exon 9 in the ADAM10 gene encodes
the zinc binding domain of the protease active site and cre-mediated deletion causes a
frameshift mutation, which disrupts transcription. CD19 is expressed starting at the proB cell stage, but CD19-cre recombination is limited to the immature B cell or pre-B cell
[173]. To confirm B cell specific ADAM10 deletion, PCR analysis for exon 9 was
performed on B220+ B cells and B220- splenocytes [52]. C57- ADAM10B-/- mice were
then crossed with YFP reporter mice, which have a floxed stop codon upstream of a
YFP reporter gene. Successful recombination defined by YFP expression using flow
cytometry analysis indicated 87% of splenic B cells and 95% of peripheral lymph node B
cells in C57-ADAM10B-/- were YFP positive [52]. Therefore, this mouse only expresses
YFP after cre-mediated recombination in B cells as outlined in Figure 2. Balb/c
ADAM10B-/- (Balb-ADAM10B-/-) mice were generated by crossing C57-ADAM10B-/- to
Balb/c WT (Jackson) for 8 generations.
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Figure 2. B cell specific ADAM10 deficient mouse model.
Cre-recombinase
recombinase (cre) is under the control of the CD19 promoter (P) on one CD19
allele. CD19 expression occurs in B cells leading to cre expression. Note, that this
allele is kept heterozygous with one WT CD19 allele to avoid disruption in CD19
expression. Cre cleaves at loxP sites that flank exon 9 of both ADAM10 alleles,
alle
which
renders ADAM10 ineffective. Additionally, these mice express a YFP reporter gene to
track successful ADAM10 deletion. Cre cleaves at loxP sites flanking a STOP
sequence upstream of the YFP
YFP-Rosa
Rosa gene. With the excision of the STOP sequence,
the YFP-Rosa
Rosa gene is transcribed and expressed on ADAM10 deficient B cells. (A) WT
genotype. Cre negative mice exhibit WT ADAM10 expression and no YFP expression.
(B) B cell ADAM10 deficient genotype. Cre positive mice express cre when CD19 is
transcribed. Cre deletes ADAM10 and the STOP sequence, thus YFP is expressed.
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1.3.2 Humoral immune responses in C57-ADAM10B-/- deficient mice
Figures 3-6 are presented as background work performed by Dr. Joanna Cichy
and Dr. Natalia Chaimowitz prior to my project.
ADAM10 is highly expressed on GC B cells
Because ADAM10 cleaves many substrates potentially involved in B cell humoral
responses including Notch 1, Notch 2, TNF, and CD23 [1,174,175], our lab in
collaboration with Joanna Cichy from Jagiellonian University, Krakow, Poland
investigated the expression of ADAM10 on GC B cells. Peyer’s patches (PPs) are a
secondary lymphoid tissue located in the intestine and exhibit a high level of GC activity.
Flow cytometric analysis of WT PPs demonstrated that 2% of naïve B cells express
ADAM10 while 80% of GC B cells are ADAM10+ (Figure 3A, B). Increased ADAM10
expression on GC B cells was confirmed by immunoflourescent staining of sectioned
PPs (Figure 3C). Taken together, ADAM10 is expressed highly in GC B cells.
Reduced total and antigen specific humoral responses in C57-ADAM10B-/- mice
Given that ADAM10 is expressed highly on GC B cells, both total and antigen
specific antibody responses were next examined. Basal levels of total IgM, IgG1,
IgG2a, and IgG2b from naïve mice were reduced in C57-ADAM10B-/-, suggesting a
defect in antibody production (Figure 4A). Next, mice were immunized i.p. with NPKLH (NP) in alum and antigen specific antibody production was assessed. NP-specific
IgM was reduced in C57-ADAM10B-/- mice 7 days post immunization, but reached WT
levels by day 14 and remained comparable at day 21 and 28 (Figure 4B). Both total
and high affinity NP-specific IgG were significantly reduced C57-ADAM10B-/- mice at day
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7, 14, 21, and 28 post immunization (Figure 4B). When boosted with NP-KLH at day
42 post immunization, total and high affinity IgG antibody titers still failed to recover to
WT levels (Figure 4C). NP-specific IgG1, IgG2a, and IgG2b were assessed at day 28
and were reduced in C57-ADAM10B-/- compared to WT (Figure 5A). Furthermore,
immunization with 1mg of NP-KLH in alum still revealed reduced NP-specific IgG
responses in C57-ADAM10B-/- demonstrating that increased antigen dose cannot
overcome the antibody defect (Figure 5B).
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Figure 3. ADAM10 expression on GC B cells.
(A and B) Expression of ADAM10 on gated GC PNAhiIgDlo (blue) and naive PNAloIgDhi
(red) B cells (CD19+) isolated from PPs. Flow cytometry gates used to define the GC
and naive B cell populations are indicated on the left. To demonstrate specificity
specificit of
staining, we used isotype-matched
matched monoclonal antibody (mAb). (A) Gating protocol is
shown. (B) Percentage of ADAM10+ cells in naive and GC B cells. (C) Frozen serial
sections of PPs were stained to detect B cell follicles (B220+, blue), GCs (PNA+, green),
and ADAM10 (red) (right panel) or isotype matched mAb (left panel). Original
magnification 20x. The mucosal epithelium (E) (left panel) also reacts with PNA and
anti-ADAM10.
ADAM10. Figure courtesy of Joanna Cichy, from Jagiellonian University, Krakow,
Poland.
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Figure 4. C57-ADAM10B−/− mice have impaired humoral responses
responses.

(A) Serum total IgM, IgG1, IgG2a, and IgG2b were measured by ELISA from naive 88 to
12-wk-old
old mice. (B) ADAM10B−/− mice and WT littermate controls were immunized with
10µg NP-KLH
KLH emulsified in alum. At the indicated times, serum samples were collected
and total NP-specific
specific IgM, total IgG, and high
high-affinity
affinity IgG antibody titers were
determined by ELISA, with NP
NP-16–BSA as
s capture Ag for total and NP-4–BSA
NP
as
capture Ag for high-affinity
affinity ELISA. (C) Mice were immunized with NP
NP-KLH
KLH emulsified in
alum, rested for 42 d, and boosted with 10 µg NP-KLH
KLH for 5 d. Mice were bled weekly
throughout the course of the experiment. Total and high-affinity Ag-specific
specific IgG levels
were measured by ELISA at each time point. The relative unit (RU) values for alumalum
B-/injected mice were <0.001. WT (white bars) and ADAM10 (black bars) and. Bars
represent the mean ± SEM of five to nine mice per group (*p < 0.05, **p < 0.01, ***p <
0.001). Data represent results obtained in at least two independent experiments. Figure
courtesy of Dr. Natalia Chaimowitz.
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Figure 5. Decreased NP-specific IgG secretion is not IgG subset dependent and
cannot be overcome by high antigen dose.
(A) ADAM10B-/- mice and WT controls were immunized with 10µg NP-KLH emulsified in
alum. Twenty-eight days after primary immunization, samples were collected and NPspecific IgG1, IgG2a and IgG2b antibody titers were determined by ELISA with
NP14BSA as capture antigen. (B) ADAM10B-/- and WT controls were immunized i.p. with
1mg of NP-KLH emulsified in alum. Samples were collected at the indicated time post
immunization, and NP-specific antibodies were measured. The relative unit (RU) values
for alum-injected mice were <0.001. WT (white bars) and ADAM10B-/- (black bars).
Bars represent the mean ± SEM of 5 mice per group. Data represents results obtained
in two independent experiments. (*p<0.05, **p<0.01, ***p<0.001). Figure courtesy of
Dr. Natalia Chaimowitz.
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1.3.3 Aberrant secondary lymphoid tissue architecture, TNF, and ADAM17 in C57ADAM10B-/- mice
Reduced GC B cells in C57-ADAM10B-/- spleen
Figures 4 and 5 demonstrated that C57-ADAM10B-/- mice exhibit impaired
antibody production and most impressively impaired class-switched antibody
production. Because class switching occurs in germinal centers, we next enumerated
GC B cells (IgMloIgDloB220+IgG1+CD38lo) by flow cytometry (Figure 6A). Following 14
or 21 days post NP-KLH/alum immunization, splenic GC B cells were reduced by both
percentage (Figure 6B) and total number (Figure 6C) in C57-ADAM10B-/- mice
compared to WT.
C57-ADAM10B-/- mice exhibit abnormal lymph node architecture and excessive TNF in B
cell regions
In addition to reduced GC B cell numbers, Chaimowitz et al. described secondary
lymphoid tissue architecture defects in immunized LNs isolated from C57-ADAM10B-/mice, which supported the reduced antibody production noted in these mice [107].
These defects included improper localization of B and T cells, reduced germinal center
formation, and a decrease in follicular dendritic cell (FDC) networks [107]. These
architecture aberrancies bore some similarity with secondary lymphoid tissue defects
noted in early studies of global TNF deficient mice. Specifically, lack of splenic B cell
follicles, disorganized FDC networks, and aberrant germinal centers [32]. Recent
studies using B cells only capable of expressing mTNF showed that sTNF produced by
B cells is required for maintaining secondary architecture and for IgG production against
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T dependent antigens [34]. Taken together, B cell ADAM10 and TNF are both critical in
maintaining proper secondary lymphoid architecture and class switched antibody
production, but a link between them is still unclear.
Figure 7 shows immunohistochemistry analysis of lymph nodes from naïve (nonimmunized) WT and C57-ADAM10B-/- mice. While initial studies had indicated a
relatively normal architecture in C57-ADAM10B-/- nodes in the absence of immunization
[107], additional analysis revealed that not only are lymph node FDC networks largely
absent and B/T boundaries intermingled (Figure 7A, 7B), but other abnormalities can
also be seen. These changes include excessive collagen deposition as well as an
increase in high endothelial venules (HEVs), especially within B cell cortical regions
(Figure 7B, C). Most striking, however, was the dramatic increase in TNF within the B
cell regions of C57-ADAM10B-/- nodes (Figure 7D). Given the data in Figure 7 and
previous reports of secondary lymphoid tissue architecture abnormalities in TNF
knockouts and those only capable of expressing mTNF, it appears that not only
subnormal but also excessive TNF levels in the lymph node cortices may lead to
disruption of normal follicular architecture.
B cells from C57-ADAM10B-/- mice exhibit increased expression, stability and production
of TNF
Given the excessive TNF staining in B cell regions of C57-ADAM10B-/- lymph
nodes (Figure 7), we further analyzed differences in TNF expression and production in
B cells purified from both C57-ADAM10B-/- and WT mice. As can be seen in Figures 8A
and 8B, flow analysis for mTNF revealed that both naïve and stimulated C57-ADAM10B-
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/-

B cells exhibit increased mTNF. Furthermore, ELISA analysis of supernatants from

C57-ADAM10B-/- B cells cultured with LPS/IL-4 (Figure 8C) or anti-CD40/IL-4 (Figure
8D) for 1, 3, or 5 days all showed significantly higher sTNF production compared to WT.
Relative (Figure 9A) and absolute (Figure 9B) TNF message analysis by qPCR
indicated a strong increase in TNF message in C57-ADAM10B-/- compared to WT B
cells post stimulation in vitro. Furthermore, Tristetraprolin (TTP), which promotes TNF
mRNA degradation [176,177], was reduced 2 fold in C57-ADAM10B-/- B cells (Figure
9C), which have increased sTNF and mTNF (Figure 8) compared WT B cells. The
combined results of increased TNF message as well as membrane and soluble protein,
suggests a possible feedback mechanism in which increased TNF shedding
upregulates further TNF production. In any case, it is clear that TNF is increased at
both the message and protein level in C57-ADAM10B-/- B cells.
C57-ADAM10B-/- B cells exhibit higher ADAM17 gene and protein expression
ADAM17 is known to be the principle sheddase of membrane bound, pro-TNF.
Since, C57-ADAM10B-/- B cells exhibit higher expression and production of TNF, we next
examined ADAM17 expression and function by analyzing ADAM17 message (Figure
10A, 10B) and protein levels (Figure 10C, 10D) in WT compared to C57-ADAM10B-/- B
cells. While both naïve and stimulated C57-ADAM10B-/- B cells express significantly
more ADAM17 message (Figure 10A, 10B), relative gene expression analysis showed
that in the naïve state, C57-ADAM10B-/- B cells express 2 times higher ADAM17
compared to WT, which increased to 5 fold higher expression upon stimulation (Figure
10A). Similarly, absolute RNA quantification revealed that naïve C57-ADAM10B-/- B
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cells exhibit significantly increased ADAM17 mRNA expression, which increases further
upon stimulation (Figure 10B). Western blot analysis, furthermore, showed a 2.3 fold
increase in ADAM17 protein levels in naïve C57-ADAM10B-/- B cells over WT, which too
increased upon stimulation to 5 fold (Figure 10C, 10D). Upon overexposure of the
blots, both the precursor and glycosylated forms of ADAM17 were seen (data not
shown).
In addition, Vandenbroucke et al. recently established that matrix
metalloproteinase MMP13 also cleaves TNF at least in intestinal epithelium [178].
qPCR analysis of MMP13 in naïve B cells, however, showed there was no difference
between WT and C57-ADAM10B-/- B cells (∆∆Ct = 1.04; fold change ADAM10B-/- over
WT). Western blot, furthermore, failed to show MMP13 protein in naïve WT and
ADAM10B-/- B cells compared to positive control, RAW 264.7 macrophages (data not
shown). This finding is in agreement with the report that significant levels of MMP13 are
not found in B cells [179]. Taken together, Figures 6-10 demonstrate that ADAM10
deletion from C57Bl/6 B cells results in a compensatory increase in ADAM17
expression and activity leading to excessive TNF cleavage. The aberrant signaling
environment created by this compensatory effect is an excellent candidate to explain
the abnormal lymphoid tissue architecture in our C57-ADAM10B-/- model and was thus
further explored.
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Figure 6. GC formation after T-dependent immunization.
ADAM10B−/− and WT mice were immunized with 10µg NP-KLH emulsified in alum.
Fourteen and 21 days post-immunization, flow cytometry was carried out and the
presence of GC B cells (IgMloIgDloB220+IgG1+CD38−) in the spleen of WT and
ADAM10B−/− mice was assessed. Staining protocol is depicted (A). Both percentage (B)
and total number (C) of GCs were enumerated. WT (white bars) and ADAM10B-/- (black
bars). Bars represent the mean ± SEM of eight mice per group. *p < 0.05, **p < 0.01.
Data is representative of three independent experiments. Figure courtesy of Dr. Natalia
Chaimowitz.
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Figure 7. Naïve C57-ADAM10B-/- lymph nodes (LNs) display abnormal follicular
architecture.
Compared to WT, ADAM10B-/- mice (A) lack well developed FDC reticula (red, CR1/2) in
the B cell follicle (blue, B220), (B) lack B cell/T cell (red, CD3) segregation with more
HEVs (green, pNAD) in the LN cortex, (C) display more collagen (green) deposition in
the B cell follicle, and (D) express higher levels of TNFα than WT mice. Scale bar = 50
mm, and micrographs are representatives of at least 3 LNs.

59

A

B

C

D

Figure 8. Increased TNF surface expression and production in C57-ADAM10B-/- B
cells.
Naïve (A) and 5 day stimulated (B) (LPS + IL-4) WT (black thin line) and ADAM10B-/(black bold line, A10KO) live B cells were analyzed for co-expression of TNF using
tyramide signal amplification. Black bars (overlay plots) indicate B cells staining high in
mTNF, represented in bar graphs (A,B). N=9 per group, 3 independent studies. (C,D)
Supernatants were harvested on day 1, 3, or 5 from WT (white) or ADAM10B-/- (A10KO,
black) B cell cultures stimulated with LPS + IL-4 (C) or anti-CD40 + IL-4 (D) and sTNF
determined by ELISA. N=9 per group, 3 independent studies. *indicates p<0.05, **
indicates p<0.005.
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Figure 9. Increased TNF gene expression and message stability in C57ADAM10B-/- B cells.
Naïve (3A [checkered], 3B [left], 3C [checkered]) or 5 day stimulated (LPS + IL-4) (3A
[stripe], 3B [right], 3C [stripe]) B cells were analyzed by qPCR for TNFα (A, B) and TTP
(C) message normalized to 18s. Data presented as fold change of ADAM10B-/- over WT
(A) or fold change of WT over ADAM10B-/- (C) using the (∆∆)Ct method of analysis.
Absolute RNA quantification for TNFα normalized to 18s in WT (white) and ADAM10B-/(black) B cells appears in (B). N=9 per group, 3 independent studies. *indicates p<0.05,
***indicates p<0.0005.
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Figure 10. Increased ADAM17 message and protein levels in C57-- ADAM10B-/- B
cells.
Naïve (4A [checkered],, 4B [left], 4C) or 5 day stimulated (4A [stripe], 4B [right], 4D)
(LPS + IL-4)
4) B cells were analyzed by qPCR and western blotting. (A) Relative ADAM17
expression normalized to 18s presented as fold change of ADAM1
ADAM10B-/-- (A10KO) over
WT using the (∆∆)Ct
)Ct method of analysis. (B) Absolute quantification of ADAM17 RNA
normalized to 18s. N=9 mice per group, 3 independent studies. Band densitometry of
naïve (C) and stimulated (D) B cells represents ADAM17 (~93kDa, mature form)
f
normalized to actin (~42kDa). N=6 per group total, 4 independent studies. *indicates
p<0.05.
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Reconstitution of irradiated C57Bl/6 WT with combination C57-ADAM10B-/- + TNFKO
bone marrow rectifies lymph node follicular abnormalities
In order to assess whether TNF is involved in the mechanism underlying lymph
node tissue abnormalities in C57-ADAM10B-/- mice, we performed a bone marrow
chimera experiment in which irradiated CD45.1 WT C57Bl/6 mice were reconstituted
with one of the following bone marrow combinations: (1) WT (CD45.2) alone; (2) C57ADAM10B-/- (CD45.2) alone; (3) TNF deficient (TNFKO) alone; (4) 50/50 mix C57ADAM10B-/- + WT (CD45.2); or (5) 50/50 mix C57-ADAM10B-/- + TNFKO. Following 6
weeks of reconstitution, mice were bled and analyzed for successful reconstitution and
CD45.2 cells predominated (Figure 11). The mice were then footpad immunized with
NP-KLH, and draining lymph nodes were assessed by immunohistochemistry 14 days
post-immunization (Figure 12A-H). As expected, lymph nodes from WT mice
reconstituted with WT (CD45.2) bone marrow exhibited normal lymph node architecture
(Figure 12D) and TNF levels (Figure 12G), which was comparable to non-irradiated
WT nodes (Figure 12A, 12G). Those reconstituted with C57-ADAM10B-/- bone marrow
(Figure 12B, 12G), however, had a similar phenotype to those of our C57-ADAM10B-/mice (Figure 7): loss of B cell/T cell segregation, decreased FDC networks, and
increased cortical TNF. Those reconstituted with TNFKO bone marrow alone (Figure
12C) exhibit no TNF staining but do still demonstrate FDC networks as these are
resistant to irradiation. Furthermore, reconstitution with 50/50 mix C57-ADAM10B-/- +
WT CD45.1 still yielded abnormal lymph node architecture (Figure 12E) and high TNF
staining (Figure 12G) similar to C57-ADAM10B-/-. Thus, the amount of TNF made by B
cells from this combination is still too high. Interestingly, when WT mice were
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reconstituted with combination C57-ADAM10B-/- + TNFKO bone marrow (Figure 12F,
12G), lymph node tissue architecture and TNF staining returned to WT levels. TNF
staining is further compared and quantified by mean gray values in multiple equal areas
(at least 6) in Figure 12H. Here, mice reconstituted with C57-ADAM10B-/- alone as well
as C57-ADAM10B-/- + WT CD45.1 exhibit significantly more TNF staining compared to
WT and C57-ADAM10B-/- + TNFKO (Figure 12H). We reason that while B cells from
C57-ADAM10B-/- mice produce excessive TNF, those from the TNFKO mice produce
none, thus averaging to a normal, WT range allowing proper TNF signaling to occur.
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Figure 11. Confirmation of successful bone marrow reconstitution.
Irradiated CD45.1 WT mice were reconstituted with CD45.2 (A) or C57-ADAM10B-/(CD45.2) (B) bone marrow and peripheral blood sample collected at 6 weeks post
reconstitution. Percentage of CD45.2+ live peripheral blood lymphocytes is shown.
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Figure 12. Reconstitution of irradiated WT naïve LNs with ADAM10B-/- + TNFKO
bone marrow restores normal follicular architecture and rectifies structural
abnormalities induced by ADAM10B-/- reconstitution alone.
Draining lymph node sections from non-irradiated WT (A, G (CD45.1 WT)) and
irradiated CD45.1 WT reconstituted with ADAM10B-/- (B, G (Reconstitution with
ADAM10KO)), TNFKO (C), WT CD45.2 (D, G (Reconstitution with CD45.2 WT)),
ADAM10B-/- + WT CD45.1 (E, G (Reconstitution with ADAM10KO and CD45.1 WT)),
ADAM10B-/- + TNFKO (F, G (Reconstitution with ADAM10KO and TNFKO)) were
compared in (A-F) with regards to B/T compartmentalization (left column), FDC reticular
development (middle column), and TNFα staining (right column). In (A-G) the following
stains were used: B cells (blue, B220), T cells (red, Thy1.2), Collagen 1 (green), FDCs
(red, CR1/2), and TNFα (green). White boxes in (A-F, right column) are magnified in
(G, left column), with separation of the TNFα labelling (middle column) and
measurements (histograms, right column). (H) TNFα expression (mean gray values) in
multiple equal areas (at least 6) have been calculated and the results expressed as
mean + SD. Using unpaired T test, the p value between CD45.1 WT and reconstitution
with CD45.2 WT is 0.33; CD45.1 WT and reconstitution with ADAM10KO and TNFKO is
0.36; and reconstitution with ADAM10KO and ADAM10KO and CD45.1 WT is 0.2.
Micrographs are representative of at least 3 LNs from 3 independent experiments.
Scale bar in A-F = 50 mm, in G = 20 mm.
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Figure 12. Reconstitution of irradiated WT naïve LNs with ADAM10B-/- + TNFKO
bone marrow restores normal follicular architecture and rectifies structural
abnormalities induced by ADAM10B-/- reconstitution alone.
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1.3.4 Balb-ADAM10B-/- exhibit reduced antigen specific antibody production and
GC B cells similar to C57-ADAM10B-/- mice
Similar to C57-ADAM10B-/- mice, we characterized antibody production by BalbADAM10B-/- mice following NP-KLH immunization in alum. At day 7 post immunization,
NP-specific IgM was reduced in Balb-ADAM10B-/- serum and IgG1 was very lowly
detected (Figure 13A, 13B). At day 14, NP-specific IgM and IgG1 were significantly
reduced in Balb-ADAM10B-/- compared to Balb-WT as expected given our results in
C57Bl/6 mice (Figure 13A,13B). Given the reduction in class-switched antibody
production, we next wanted to assess the percentage of GC B cells in the draining LN of
Balb-ADAM10B-/- compared to WT. Unlike C57-ADAM10B-/- (Figure 6B), the BalbADAM10B-/- lymph nodes exhibited a normal percentage of GC B cells compared to
Balb-WT (Figure 13C). This finding was unexpected given our results in C57ADAM10B-/- and thus prompted an architecture analysis of Balb-ADAM10B-/- lymph
nodes as well as characterization of ADAM17 and TNF production by Balb-ADAM10B-/B cells.
1.3.5 Th1 and Th2 strain dependent differences in B cell ADAM17 and TNF as well
as secondary lymphoid tissue architecture following B cell ADAM10 deletion
Strain dependent differences in B cell TNF and ADAM17
C57-ADAM10B-/- B cells exhibit a compensatory increase in ADAM17 expression
and function resulting in excessive TNF cleavage, which provided the mechanism for
the aberrant secondary lymphoid tissue architecture noted in these mice [31,107]
(Figure 7-12). We, therefore, analyzed both TNF and ADAM17 expression and function
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by Th2 prone Balb/c WT (Balb-WT) and Balb-ADAM10B-/- compared to C57Bl/6 WT
(C57-WT) and C57-ADAM10B-/- B cells to see if differences in B cell TNF and ADAM17
exist between strains. First, sTNF production by Balb-WT and Balb-ADAM10B-/- B cells
was comparable following in vitro stimulation unlike our previous report in C57Bl/6
(Figure 14A). Furthermore, mTNF in stimulated B cells is comparable between BalbWT and Balb-ADAM10B-/- but reduced compared to C57-WT and even further reduced
compared to C57-ADAM10B-/- (Figure 14B). Similarly to C57, Balb-WT and BalbADAM10B-/- express comparable TNF message in the naïve state (Figure 14C). Upon
stimulation, however, Balb-ADAM10B-/- B cells fail to significantly increase TNF
message above Balb-WT levels unlike C57-ADAM10B-/- B cells (Figure 14C).
Furthermore, C57-ADAM10B-/- B cells exhibit increased TNF message compared to
Balb-ADAM10B-/- (Figure 14C).
Given that TNF levels were reduced in Balb-ADAM10B-/- compared to C57ADAM10B-/- B cells, we next compared the levels of ADAM17 protein and message.
C57-ADAM10B-/- B cells exhibited increased ADAM17 protein compared to C57-WT, but
also compared to Balb-WT and most interestingly, Balb-ADAM10B-/- (Figure 15A).
Furthermore, ADAM17 protein was comparable between Balb-WT and Balb-ADAM10B-/(Figure 15A), which is consistent with TNF production in Figure 14A. Unlike C57Bl/6,
ADAM17 message in naïve Balb-WT and Balb-ADAM10B-/- B cells was comparable and
increased to 2-fold higher expression upon stimulation (Figure 15B).
Unlike C57-ADAM10B-/-, Balb-ADAM10B-/- exhibit normal secondary lymphoid tissue
architecture.
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We previously noted the defects in secondary lymphoid tissue architecture in
C57-ADAM10B-/- lymph nodes (Figure 7), including aberrant B cell/T cell localization,
decreased FDC development, excessive collagen deposition, decreased germinal
center formation, and increased HEV formation, was attributed to increased B cell
ADAM17 resulting in excessive B cell TNF production and signaling within the follicle
[31]. Given the marginal changes in TNF (Figure 14) and ADAM17 (Figure 15) in BalbADAM10B-/-, however, compared to C57-ADAM10B-/- [31] (Figures 7-12), we
hypothesized Balb-ADAM10B-/- lymph nodes would maintain WT architecture. Indeed,
Balb-ADAM10B-/- exhibited comparable primary follicular characteristics to C57-WT and
Balb-WT, including normal B cell/T cell compartmentalization (Figure 16A), number
and size of HEVs (Figure 16A), FDC reticular (Figure 16B), and collagen deposition
(Figure 16B). Again, C57-ADAM10B-/- lymph node sections are provided as a reference
as they exhibit a lack of B/T compartmentalization, increased HEVs, minimal CD21+
FDC reticula, and excess collagen deposition. Furthermore, TNF labeling (boxed
regions of Figure 16C) demonstrated that C57-ADAM10B-/- follicles displayed the
highest TNF intensity compared to C57-WT, Balb-WT, and Balb-ADAM10B-/- (Figure
16C), with the latter groups all having comparable TNF staining (Figure 16C), which is
quantified in Figure 16D. These results provide further support that excess B cell sTNF
underlies the aberrant lymphoid tissue architecture in C57-ADAM10B-/- mice and
demonstrates the inherent difference in B cell ADAM10 and ADAM17 regulation in Th1
vs. Th2 prone mice.
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Figure 13. Balb-ADAM10B-/- mice exhibit reduced NP-specific antibody production
but a normal percentage GC B cells.
Balb-WT (WT) (white bars) and Balb-ADAM10B-/- (Balb-A10KO) (black bars) were
immunized i.p. and f.p. with NP-KLH in alum and bled at day 7 and 14 post
immunization. Serum levels of NP-specific IgM (A) and IgG1 (B) were determined at
day 7 and day 14 post immunization. (C) At day 14, draining axillary LNs were
analyzed for GC (B220+GL7+) B cells and percentage compared to total B220+ B cell
population. Error bars represent SD; *p<0.05, **p<0.005, ***p<0.0005.
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Figure 14. Differential TNF production and expression in C57Bl/6 and Balb/c
ADAM10B-/- (A10K0) and WT B cells.
(A) Supernatants were harvested on day 3 from C57Bl/6 (left) or Balb/c (right) WT
(white) or A10KO (black) B cell cultures stimulated with LPS + IL-4 and sTNF
determined by ELISA. (B) Balb/c WT (black), Balb/c A10KO (red), C57Bl/6 WT (green),
and C57Bl/6 A10KO (blue) B cells stimulated 3 days with LPS + IL4 were analyzed for
coexpression of TNF using TSA. (C) Naïve (white) or 3 day stimulated (black) B cells
were analyzed by qPCR for TNF message normalized to 18s. Data presented as fold
change of A10KO over WT for C57Bl/6 (left) and Balb/c (right) using the ∆∆Ct method of
analysis. n = 9 per group, three independent studies. *p < 0.05, **p < 0.005.
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Figure 15. Increased ADAM17 in C57Bl/6 WT and A10KO over Bal
Balb/c
b/c WT and
A10KO, respectively.
(A) 5 day stimulated B cells were analyzed by western blot (left) for ADAM17 (~93kDa)
relative to actin (~42kDa) and band densitometry shown (right). (B) Relative ADAM17
expression normalized to 18s for naïve (white) or 3 day stimulated (black) B cells
presented as fold change of ADAM10
ADAM10KO over WT using the ∆∆Ct
Ct method of analysis.
n=9 per group, three independent studies. *p < 0.05, **p < 0.005.
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Figure 16. Balb-ADAM10B-/- lymph nodes exhibit WT architecture unlike C57C57
B-/ADAM10 nodes.
Naïve lymph node sections from C57Bl/6 and Balb/c WT (right) and ADAM10B-/- (left)
were analyzed for (A) B cell (blue, B220)/T cell (red, Thy1.2) localization and HEV
H
formation (green, pNAD); (B) FDC reticula (red,CR1/2) development, collagen (green)
deposition, and presence of a distinct cortico
cortico-medullary
medullary junction (dotted line in inset box,
B-/Balb-ADAM10 only); (C) TNF staining (green) within B cell (blue, B220) follicle
f
regions. (D) Average TNF staining intensity from 12 follicle sections (represented by box
in (C)), **p<0.005. Scale bar is 50 µm. Micrographs are representative of at least 3
LNs.
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Chapter 4: Th1 and Th2 prone mouse strains and humans exhibit differential B
cell ADAM10, ADAM17, and TNF levels

1.4.1. Th2 prone strains (Balb/c, A/J) B cells exhibit increased ADAM10 and
decreased ADAM17 and TNF compared to those of Th1 prone strains (C57Bl/6,
SJL/J)
Based on results described in Figures 14-16, clear differences in TNF and
ADAM17 exist between C57-WT and Balb-WT B cells. Therefore, we aimed to confirm
if differences in TNF, ADAM10, and ADAM17 exist between other Th1 and Th2 prone
strains. Because Th2 prone mouse strains are more susceptible to models of airway
hyper-reactivity and increased B cell ADAM10 correlated with exacerbated airway
symptoms and immunopathology in mice, we hypothesized that Th2 prone mouse
strains would exhibit increased B cell ADAM10 and reduced ADAM17 and TNF
compared to Th1 counterparts [180]. In fact, naïve B cells from Th2 prone Balb/c and
A/J expressed higher total ADAM10 (Figure 17A) and decreased total ADAM17 (Figure
17B) compared to Th1 prone C57Bl/6 and SJL/J. Upon stimulation in vitro, B cells from
the chosen Th1 prone strains expressed increased mTNF compared to the chosen Th2
prone strains (Figure 17C). Furthermore, TNF message was lower in Th2 prone A/J
and Balb/c mice compared to C57Bl/6 WT by ≥2 fold (Figure 17D). C57Bl/6 WT TNF
expression was not significantly different from SJL/J (Figure 17D). B cell ADAM10 in
both Th1 prone-C57Bl/6 and Th2 prone-Balb/c strains increased following in vitro
stimulation (Table 4). However, Th2 prone Balb/c maintained a consistently higher
level of B cell ADAM10 even after equal stimulation (Table 4). This finding
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demonstrates that T cell help, in the form of anti-CD40/IL-4 or anti-CD40 alone,
augments ADAM10 expression but does not provide the entire explanation for why B
cell ADAM10 is initially increased in Th2 prone over Th1 prone strains.
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Figure 17. Increased B cell ADAM10 and decreased ADAM1
ADAM17
7 and TNF in Th2
biased strains.
Naïve B220+ B cells (A, B) stained for total ADAM10 (A) or ADAM17 (B) expression by
flow cytometry. (C) Surface TNF expression on 3 day stimulated (anti-CD40+IL4)
CD40+IL4) B220+
B cell by TSA. (A,B,C) Bar graph represents percent total B cells staining high in
ADAM10 (A), ADAM17
M17 (B), or TNF (C). (A,B,C) Balb/c ((──)A/J (----),
), C57Bl/6 (▬▬),
(
SJL (▪▪▪▪▪),
), respective isotype control (shaded grey) in representative overlay (left); grey
gate demonstrates high stained population. n = 8 per group, 3 independent studies.
*p<0.05, **p<0.005,
.005, ***p<0.0005. (D) TNF message from 3 day stimulated (anti-CD40
(anti
+
+
IL4) B220 B cells. Presented as fold change from C57Bl/6 WT. * signifies ≥2 fold
change between groups.
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Table 4. ADAM10 expression in Naïve and Stimulated WT B cells by qPCR.

Balb naïve / C57 naïve

Average Fold Change in ADAM10
mRNA expression (±SD) using
∆∆Ct
2.35 ± 1.00

Balb A+I / Balb naïve

2.02 ± 0.66

C57 A+I / C57 naïve

2.40 ± 1.34

Balb A / Balb naïve

2.88 ± 1.45

C57 A / C57 naïve

1.91 ± 0.30

Balb A+I / C57 A+I

5.34 ± 1.84

Balb A / C57 A

5.70 ± 1.45

Comparison

A+I (3 days stimulation with anti-CD40+IL4); A (3 day stimulation with anti-CD40 alone).
ADAM10 expression normalized to 18s. Fold change in gene expression of 2 or more
between groups considered significant.
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1.4.2 High B cell ADAM10 predicts increased susceptibility to Th2 disease
High B-ADAM10 level in the context of a Th2 environment allows optimal induction of
allergic airway disease symptoms
C57Bl/6 WT exhibit a decreased response to mouse lung inflammation models
compared to Balb/c including airway bronchoconstriction and IgE production, however,
these findings have never been linked to B cell ADAM10 levels, specifically
[31,181,182]. Our results thus far indicate that Th2 prone mice, whose B cells are
known to produce excess IgE post immunization, exhibit increased B cell ADAM10 even
in a naïve, non-stimulated state. After stimulation with anti-CD40/IL-4 (Table 4), B cell
ADAM10 levels increased more dramatically in Th2 prone strain B cells as well.
Therefore, we next sought to compare the consequences of B cell ADAM10 level in the
context of a Th1 or Th2 immune-environment on acute airway hypersensitivity induction
following house dust mite (HDM) challenge (Figure 18), specifically with regards to IgE
production. The groups considered included: B cell ADAM10 high, Th2 prone (Balb/c
WT); B cell ADAM10 low, Th1 prone (C57 WT); B cell ADAM10 deleted, Th2 prone
(Balb-ADAM10B-/-); and B cell ADAM10 deleted, Th1 prone (C57-ADAM10B-/-). When
each group was treated intranasally with saline, all disease parameters were similar (not
statistically different). For clarity, saline treated Balb WT was chosen as the
representative saline group in Figures 19 and 20.
Th2 prone, B cell ADAM10 high Balb WT exhibit the most severe induction of
lung inflammation following HDM challenge, including increased bronchoconstriction
(Figure 19A) and inflammatory, cellular infiltrate in lung tissue (boxed regions at 10x
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magnification in Figure 20A, 20C). Similarly, Balb WT exhibit the highest goblet cell
metaplasia as indicated by the intense pink staining mucin (arrows in Figure 20B) and
mucus (MUC5AC protein) production (Figure 20D). Furthermore, the thickness of the
alveolar epithelium (Figure 20B) is greatest in the Balb/c compared to other groups with
the C57-ADAM10B-/- being reflective of saline controls. In accordance with our main
hypothesis that increased B cell ADAM10 lends to increased IgE production, Balb WT
exhibited the highest HDM-specific IgE (Figure 19C) as well. When ADAM10 is deleted
from B cells but remains in the context of a Th2 environment in the Balb-ADAM10B-/-,
bronchoconstriction (Figure 19A), goblet cell hyperplasia (Figure 20B), and mucus
production (Figure 20D) are reduced significantly from Balb WT and are quite similar to
the Th1 prone, B cell ADAM10 low C57-WT. Furthermore, HDM-specific IgE (Figure
19C) is reduced from Balb WT levels demonstrating the critical importance of B cell
ADAM10 for IgE production even in a Th2 prone environment. Lastly, B cell ADAM10
deletion in the context of a Th1 environment (C57-ADAM10B-/-) provides the least
suitable context for allergic airway disease induction. Thus, as indicated previously,
C57-ADAM10B-/- mice exhibited bronchoconstriction (Figure 19A), cellular infiltration of
lung tissue (Figure 20A, 20C), goblet cell metaplasia (Figure 20B), and mucus
production (Figure 20D) similar to saline control. While the HDM-specific IgE ELISA
was not sensitive enough to detect differences between saline, C57-WT, and C57 and
Balb-ADAM10B-/-, it does indicate the importance of both ADAM10 and strain
background in IgE production as both the Balb-ADAM10B-/- and C57-WT demonstrated
significantly reduced HDM-specific IgE production compared to Balb WT (Figure 19C).
Although anticipated, this is the first time reduced IgE production has been
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demonstrated in both C57 and Balb-ADAM10B-/- mice. Furthermore, B cell ADAM10
deletion from Balb or C57 fails to reduce eosinophil recruitment in BALF, but it appears
to be a strain dependent phenomena as Balb/c mice regardless of B cell ADAM10
presence had increased eosinophils compared to C57 WT and C57-ADAM10B-/- (Figure
19B).
Allergic patients exhibit increased B cell ADAM10, CD23 cleavage, and IgE yet reduced
ADAM17 and TNF
Our results thus far indicate that mouse strains with higher B cell ADAM10 have
increased susceptibility to airway hyperreactivity induction, especially when in a Th2
context. Furthermore, B cells from Th2 prone strains exhibit increased B cell ADAM10
and reduced ADAM17 and TNF. In humans, we define “Th2 context” as patients
actively suffering from allergic rhinitis, a Th2 disease. Our goal was to characterize the
B cell phenotype of active allergic rhinitis patients and compare it to patients without a
history of atopic disease (controls). Naïve peripheral B cells from 16 allergic patients
exhibited significantly increased B cell ADAM10 compared to 16 controls (Figure 21A)
by flow cytometric analysis. Contrastingly, peripheral blood T cells (Figure 21B) and
monocytes (Figure 21C) from allergic and control patients revealed comparable
ADAM10 expression. Thus, only B cell ADAM10 expression served as an allergyassociated differential indicator. Following 5 days of stimulation in vitro with IL-21/IL4/anti-CD40, allergic-B cell supernatants demonstrated increased sCD23 indicating
higher ADAM10 activity in allergic patient B cells compared to controls (Figure 21D).
This finding supports a previous report that demonstrated increased circulating sCD23
in allergic patient’s sera [183]. Furthermore, B cell ADAM10 message in allergic
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patients was increased nearly 5-fold, while ADAM17 and TNF message were decreased
2-fold compared to controls (Figure 21E).
Given that increased B-ADAM10 leads to increased IgE production through
CD23 cleavage [30], we next compared serum antigen-specific IgE between allergic
and control patients. We were reliant on each patient self-reporting a specific antigen to
which he/she was allergic in order to perform an antigen specific ImmunoCAP [184].
Five of 16 allergic patients self-reported HDM sensitivity and ImmunoCAP demonstrated
positive HDM specific IgE levels (>0.35 kuA/I) (Figure 21F). Five control patients, who
are also quite likely exposed to HDM daily but do not develop allergy, demonstrated
negative ImmunoCAP results (all <0.35 kuA/I) or very low levels (0.41kuA/l) (Figure
21F). We next compared each individual patient’s HDM-specific IgE result to his/her
respective B cell ADAM10 expression (Table 1). In general, all control patients
exhibited very low or negative HDM specific IgE and low ADAM10 expression (< 25%)
(Table 5). As HDM specific IgE levels increased, B cell ADAM10 expression also
increased in allergic patients. One allergic patient, however, had a lower HDM specific
IgE result at 5.4 kuA/l but demonstrated a high B cell ADAM10 level (69%) (Table 5).
Overall, Figure 21 and Table 5 demonstrates a correlation between increased serum
antigen-specific IgE and increased B cell ADAM10 in allergic patients.
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Figure 18. HDM lung inflammation protocol.
Mice were intranasally (I.N) exposed to HDM or saline (black arrow) and on day 15
analyzed for AHR, BALF cell distribution, and lung tissue was collected for sectioning.
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Figure 19.. B cell ADAM10 deletion attenuates bronchoconstriction and HDM
specific IgE.
Airway resistance (cmH20.s/mL) with increasing doses of methacholine (left); Balb-WT
Balb
(──,○), Balb-ADAM10B-/-(-------,●), C57-WT (──,□), C57-ADAM10B-/- (-------,■), Saline
(──,●) presented
esented as fold increase from saline control. All mice immunized with saline
demonstrated comparable results. For simplicity, saline represents Balb WT mice given
saline. Bar graph (right) represents 25 mg/mL methacholine dose. (B) Percent
macrophages (left)
eft) and eosinophils (right) from total BALF determined by flow
cytometry; Saline control (white), Balb WT (checkered), Balb
Balb-ADAM10B-//- (dotted), C57
WT (slash), and C57-ADAM10B
ADAM10B-/- (black). (C) HDM specific IgE production. n=7-9
n=7 per
group, 3 independent experiments.
xperiments. *p<0.05, **p<0.005, ***p<0.005.
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Figure 20. B-ADAM10
ADAM10 deletion reduces cellular infiltration, goblet cell metaplasia,
and mucus production in a strain dependent manner.
(A) H&E
E stain for lung tissue demonstrates inflammatory cellular infiltration (red box);
10x magnification, scale bar 200 µm. (B) Goblet cell metaplasia determined by PAS
stain; note dark pink mucin producing cells (black arrow) and alveolar epithelium
thickness;
s; 20x magnification, scale bar 100 µm. (C) Lung pathology score representing
quantitation of inflammatory cellular infiltration on H&E stained lung sections; 2 sections
per mouse and at least 4 mice per group were assessed. (D) MUC5AC protein. n=7-9
n=7
per group,
roup, 3 independent experiments. All mice immunized with saline demonstrated
comparable results. For simplicity, saline represents Balb WT mice given saline.
*p<0.05, **p<0.005.
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Figure 21: Allergic patient B cells exhibit increased ADAM10 and sCD23 but
decreased ADAM17 and TNF.
(A) Total ADAM10 in naïve CD19+ B cells from control (thin line, open dot) and allergic
(bold line, black dot) patients; dot plot (right) shows percent of total B cells staining high
in ADAM10 (grey gate). Isotype control is shaded grey in histogram. (B,C) Total
ADAM10 on naïve T cells (B) and monocytes (C). (D) sCD23 from control (open dot) or
allergic (black dot) supernatants. (E) Naïve B cells from 4 allergic and 4 control patients
analyzed for ADAM10, ADAM17, and TNF message normalized to GAPDH.
Significance (*) indicates ≥ 2 fold cchange
hange between groups. (F) HDM specific IgE levels
in sera of control (open dot) or allergic (black dot) patients determined by ImmunoCAP.
<0.35kuA/l considered a negative result. *p<0.05, **p<0.005, ***p<0.0005.
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Table 5. Increased HDM specific IgE correlates with increased B cell ADAM10
expression.
Control
Allergic
HDM Specific IgE
Percent
HDM Specific IgE
Percent
(kuA/l)
CD19+ADAM10high
(kuA/l)
CD19+ADAM10high
<0.35
13
5.4
69
<0.35
18
12.8
48
<0.35
22
15.0
51
<0.35
25
18.0
60
0.41
15
22.0
72
Direct comparison of individual patient’s HDM specific IgE determined by ImmunoCAP
and B cell ADAM10 expression determined by flow cytometry.
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Chapter 5: C57-ADAM10B-/- B cells exhibit a B10 phenotype with enhanced ICOSL
expression and induction of T regulatory cells in secondary lymphoid tissues.
While excessive B cell TNF explained the mechanism underlying aberrant
secondary lymphoid tissue architecture in C57-ADAM10B-/-, it does not explain the
deficit in class-switched antibody production post immunization because both C57 and
Balb-ADAM10B-/- mice demonstrated reduced antibody levels (Figures 4 and 13).
Therefore, we next sought to explain the mechanism by which loss of B cell ADAM10
causes reduced antigen-specific antibody production.
1.5.1 Increased B10 cells in C57-ADAM10B-/- mice
B10 cells are a unique subset of B cells that produce the anti-inflammatory
cytokine, IL-10. Classically, their surface markers are defined as CD1d+CD5+IgDloIgMhi
or B220+IL-10+ [145]. Maseda et al. described that of the B10 cell population, only a
subset will become antibody secreting plasma cells [164]. Given the reduction in
antibody production in C57-ADAM10B-/- mice, we hypothesized that a larger portion of
their B cells may be B10 cells. We used flow cytometry to assess the percentage of
B220+IL-10+ B cells present following 3 days of stimulation in vitro with anti-CD40/IL-4.
Of the total B220+ B cell population, 30% of C57-ADAM10B-/- B cells expressed IL-10
compared to only 10% of WT B cells (Figure 22A). We chose not to define B10 cells as
CD1d+CD5+IgDloIgMhi because these markers overlap with MZ B cell markers and the
C57-ADAM10B-/- mice lack MZ B cells [52], which may affect interpretation of the data.
Furthermore, soluble IL-10 production by 3 day stimulated (anti-CD40/IL-4) C57ADAM10B-/- B cells was 3 fold higher compared to WT (Figure 22B). While B cell IL-10
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message was comparable in naïve WT and C57-ADAM10B-/- B cells, following in vitro
stimulation (anti-CD40/IL-4) for 5 days, IL-10 message increased to 6.37 fold higher in
C57-ADAM10B-/- B cells over WT (Figure 22C). We next assessed the presence of IL10 in circulation. In naïve mice, IL-10 was below levels of detection in both WT and
C57-ADAM10B-/- mice (Figure 22D). 14 days post immunization with NP-KLH in alum,
however, IL-10 levels rose to ~ 60 ng/mL in C57-ADAM10B-/- serum, which is 6 fold
higher than WT (Figure 22E).
1.5.2 Increased T regulatory cells in ADAM10B-/- mice
B cells alone are not normally thought to produce such high levels of IL-10 as
noted in Figure 22E. Treg cells, however, are a well-known IL-10 producing cell type
that may contribute to the very high levels of IL-10 seen. Furthermore, some reports
state that B10 cells enhance Treg development and function [161–163]. For these
reasons, we hypothesized that C57-ADAM10B-/-mice have increased Treg cells in
secondary lymphoid tissues, which may be explained at least in part by more B10 cells.
Immunohistochemistry revealed an increase in CD3+FoxP3+ cells in C57-ADAM10B-/spleen 14 days post immunization with NP-KLH in alum (Figure 23A and 23B). While
we are still working to optimize our staining of FoxP3+ Tregs by immunohistochemistry,
the single color sections (Figure 23A, bottom) clearly demonstrate an increase in
FoxP3+ staining in C57-ADAM10B-/- spleen. This finding was confirmed by flow
cytometry, which demonstrated increased Tregs using two conventional sets of markers
(CD4+CD25+ and CD4+FoxP3+) in both naïve (Figure 24A and 24B) and 14 day
immunized (Figure 24C) C57-ADAM10B-/- spleen.
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Figure 22. C57-ADAM10B-/- B cells have a B regulatory or B10 cell phenotype and
C57-ADAM10B-/- mice exhibit increased IL10 in circulation
circulation.
(A, B) 3 day stimulated (anti-CD40/IL
CD40/IL-4)
4) B cells have increased (A) IL10 expression by
flow cytometry and (B) IL10 secretion by ELISA. (C) IL-10
10 message in naïve (white) and
3 day stimulated (anti-CD40/IL
CD40/IL-4) (black) B cells.. Serum collected from (D) naïve mice
mic
or (E)) 14 days post immunization with NP
NP-KLH
KLH for determination of circulating IL-10
IL
by
ELISA. (A, B, E) *p<0.05;; (C) * signifies ≥ 2 fold change between WT and A10KO.
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Figure 23. Increased FoxP3+ T cells in 14 day immunized C57-ADAM10B-/- spleen.
(A) C57-WT (left) and A10KO (right) spleens stained for B cells (B220), T cells (CD3)
and FoxP3 (green). Threshold single color sections with outline (cell) counting shown
below. (B) Percent CD3+FoxP3+ compared to CD3+ alone shown in bar graph.
Representative of 3 mice/group. *p<0.02
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Figure 24. Increased Tregs in C57-ADAM10B-/- naïve and immunized spleen.
(A, B) Naive and (C) 14 day immunized spleen from WT (white, thin black line) or
A10KO (black, thin red line) were analyzed for Tregs using two surface marker
combinations: CD4+CD25+ (A,C) and CD4+FoxP3+ (B). (C) A representative overlay of
CD4+CD25+ Tregs; isotype control shaded grey; marker gate demonstrates high
staining CD25+ population. *p<0.05, **p<0.005.

92

1.5.3 Increased ICOSL expression on C57-ADAM10B-/- B cells
Given that we are using a B cell specific knockout model characterized by
increased B cell ADAM17 activity, we hypothesized that a B cell associated ADAM17
substrate or ADAM17-regulated ligand may be involved in increasing Treg development
and persistence. It is known that blockade of ICOS-ICOSL interactions in vitro impairs
Treg induction [113] and that ICOS deficiency leads to FoxP3+ Treg apoptosis and
impaired IL-10 production [114]. Furthermore, Marczynska et al. demonstrated that
ADAM17 indirectly decreases surface ICOSL and increases sICOSL production [112].
Given that C57-ADAM10B-/- B cells exhibit increased ADAM17 activity, we analyzed
ICOSL surface expression. We found that naïve C57-ADAM10B-/- B cells have
significantly increased ICOSL expression compared to naïve WT B cells (Figure 25A).
Even though C57-ADAM10B-/- B cells have increased ADAM17, this ADAM17 is not yet
active until the B cell is stimulated. Following PMA stimulation in vitro to activate
ADAM17 activity, we tracked ICOSL cleavage kinetically and found that ICOSL levels
decrease more dramatically in C57-ADAM10B-/- B cells at each time point compared to
WT (Figure 25B). Furthermore, while C57-ADAM10B-/- B cell ICOSL levels remained
very low at later time points, it appears that WT B cell ICOSL expression begins to
increase slightly starting at 60 minutes. Therefore, C57-ADAM10B-/- B cells may have a
deficient recovery of ICOSL surface levels (Figure 25B). Figure 22A demonstrated
that 30% of stimulated C57-ADAM10B-/- B cells are IL-10 producing, B10 cells. Given
that ICOSL is increased on C57-ADAM10B-/- B cells and 30% of these are B10 cells,
ICOSL may be a potential marker for B10 cells. To verify this point, we plan to stain
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B220+ cells for IL-10 and ICOSL concomitantly to verify if IL-10 producing cells express
more ICOSL than non-IL-10 producing B cells.
1.5.4 Conditioned C57-ADAM10B-/- B cell supernatants cause enhanced Treg
induction in vitro
The next central question is what the C57-ADAM10B-/- B cell is expressing or
producing that is causing an induction of Tregs. We used an in vitro Treg induction
protocol [165] to see if soluble factors released during 5 days of B cell culture with antiCD40 and IL-4 would induce FoxP3 expression in CD4+CD25- T cells. We isolated
CD4+CD25- T cells and cultured them in one of the following conditions: (1) media
alone (with IL-2/anti-CD3/CD28 co-stimulation) (negative control), (2) + recombinant
TGFβ alone (positive control), (3) + conditioned WT B cell supernatant, or (4) +
conditioned C57-ADAM10B-/- B cell supernatant. While recombinant TGFβ caused
~72% of T cells to become FoxP3+, conditioned C57-ADAM10B-/- supernatants resulted
in ~50% and WT supernatant ~12% (similar to media alone) induction of FoxP3
expression (Figure 26). We are currently testing anti-ICOSL and anti-IL10 neutralizing
antibodies in vitro to see if neutralization of either or both together will block FoxP3
induction in CD4+CD25- T cells. Furthermore, we are testing PMA stimulated WT and
C57-ADAM10B-/- B cell supernatants to see if PMA stimulation of B cells results in more
FoxP3 induction when the supernatants are cultured with CD4+CD25- T cells. We
predict there will be more induction since PMA is far better at activating ADAM17, which
we believe is controlling release of a soluble molecule (e.g. ICOSL) that is ultimately
responsible for induction of FoxP3 expression.
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As a preliminary study, we analyzed FoxP3 expression by qPCR in CD4+CD25T cells cultured with 2 hour PMA-stimulated WT or C57-ADAM10B-/- B cell supernatant
with and without ICOSL neutralizing antibody, which prevents ICOSL binding to the
ICOSR (Figure 27). Compared to CD4+CD25- T cells treated with media alone, those
cultured with C57-ADAM10B-/- B cell supernatant increased FoxP3 expression by 12
fold, which was reduced to 7 fold by the addition of ICOSL neutralizing antibody (Figure
27). Interestingly, however, WT supernatant alone still induced FoxP3 expression 7
fold, which we believe may be do to PMA remaining in the B cell supernatant (Figure
27). Therefore, we must perform a PMA only control to see if PMA alone induces
FoxP3 expression in CD4+CD25- T cells. According to Majowicz et al., CD4+CD25- T
cells cultured with PMA and anti-CD3 increased FoxP3 and CD25 expression [185].
Therefore, we may need to remove the PMA with dextrin labeled charcoal before the
co-culture. We can confirm PMA is removed by performing a CD62 ligand kinetic
shedding assay in which the supernatants with and without PMA removed are assessed
for their ability to induce CD62 ligand shedding from WT B cells. Furthermore, we will
culture WT or C57-ADAM10B-/- supernatants with an isotype control antibody to validate
our ICOSL neutralizing antibody results.
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ICOSL

Figure 25. Increased ICOSL expression and cleavage on C57-ADAM10B-/- B cells.
(A) Representative overlay of baseline ICOSL expression in naïve WT (black solid) and
C57-ADAM10B-/- splenic B cells (red). Unstained (thin dashed) and isotype control (thick
black dashed) shown. (B) ICOSL expression on WT (open dot) and C57-ADAM10B-/- B
cells (black dot) following PMA stimulation vitro.
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Figure 26. C57-ADAM10B-/- conditioned B cell supernatants induce enhanced
FoxP3 expression in CD4+CD25- T cells compared to WT B cell supernatants.
4 day stimulated CD4+CD25- T cells with cultured with IL-2/CD3/CD28 alone (green) or
IL-2/CD3/C28 plus 5 day conditioned (anti-CD40/IL-4) WT B cell supernatant (black), 5
day conditioned (anti-CD40/IL-4) A10KO B cell supernatant (red), or rTGFβ (purple).
Representative overlay of changing FoxP3 expression (left) and dot plots (right)
demonstrate percent CD4+FoxP3+ T cells following culture with rTGFβ (purple) or WT
(black) or A10KO (red) 5 day conditioned B cell supernatants.
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Figure 27.. ICOSL neutralization reduces Fox
FoxP3 expression in co-cultures
cultures of
B-/CD4+CD25- T cells with PMA
PMA-conditioned C57-ADAM10 B cell supernatants.
WT (white) or C57-ADAM10B--/- (grey) B cells were cultured for 2 hours with PMA.
Conditioned supernatants with (striped) or without (solid) anti
anti-ICOSL
ICOSL neutralizing
antibody (aICOS) or media alone (containing IL
IL-2)
2) were collected and cultured with
CD4+CD25- T cells for 4 days with plate
plate-bound
bound CD3 and CD28. FoxP3 expression
relative to GAPDH was assessed and data presented as fold change from FoxP3
expression when cultured with media alone. A fold change of ≥2
2 is considered
significant. Fold change calculated using ∆∆Ct equation.
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1.5.5. In vivo Treg depletion studies
Our next goal was to see if increased Treg cells played a functional role in the
C57-ADAM10B-/- phenotype. Specifically, is increased Tregs the mechanism underlying
decreased antigen-specific antibody production and reduced disease parameters
following HDM immunization?
HDM acute airway hypersensitivity studies with Treg depletion
In vivo depletion of CD4+CD25+FoxP3+ Treg cells can be achieved using antiCD25 (PC61mAb). Setiady et al. described that Treg depletion with anti-CD25 is
FcγRIII dependent as FcγRIII deficient mice were resistant to Treg depletion with antiCD25 [186]. Furthermore, it was FcγRIII+ macrophages, but not FcγRIII+ NK cells, that
were critical for antibody-mediated phagocytosis [186]. WT or C57-ADAM10B-/- mice
were injected i.p. 3 days before and 3 days after the first intranasal HDM challenge to
effectively deplete Tregs. The acute HDM challenge protocol was performed exactly as
described in Figure 18. All mice treated with saline regardless of i.p. injection (PBS,
COH2, anti-CD25) had statistically comparable disease parameters and are shown in
Figures 27 and 28 as a representative saline group. Similar to our previous results in
Figure 19, C57-ADAM10B-/- mice treated with COH2/HDM exhibit AHR comparable to
saline treated mice (Figure 28A). Furthermore, COH2/HDM treated WT mice have
increased AHR compared to both C57-ADAM10B-/- COH2/HDM and saline control
(Figure 28A). Interestingly, anti-CD25/HDM treated C57-ADAM10B-/- mice have
increased AHR compared to COH2/HDM treated C57-ADAM10B-/- mice and it is
comparable to COH2/HDM treated WT mice (Figure 28A). Anti-CD25/HDM treated WT
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mice exhibit the highest AHR, which is consistent with previous reports that Tregs are
important for regulating AHR in murine HDM models [139–141]. Overall, depletion of
Tregs in C57-ADAM10B-/- mice increased AHR.
Total cell number in BALF increased with anti-CD25 treatment compared to
COH2 and PBS. While this increase was significant in WT, it trended upward in C57ADAM10B-/- mice (Figure 28B). When comparing the BALF cell differential, specifically
eosinophils, varied between COH2 and anti-CD25 treated groups (Figure 28C).
Treatment with anti-CD25/HDM increased eosinophils in both WT and C57-ADAM10B-/mice compared to COH2/HDM treatment (Figure 28C). In Figure 19B, there was not a
statistical difference between HDM treated WT and C57-ADAM10B-/- mice, however
there was a trend toward reduced eosinophils as is shown in Figure 28C.
Furthermore, H&E stained lung sections were assessed from each group for both
perivascular and peribronchiolar inflammatory cellular infiltration. Intraperitoneal
injection of PBS, COH2, or anti-CD25 did not result in inflammatory cellular infiltration
as all saline treated groups lacked peribronchiolar or perivascular cell infiltration (Figure
29, top row). Anti-CD25/HDM treatment increased both perivascular and peribronchilar
inflammatory cellular infiltration in both WT and C57-ADAM10B-/- mice compared to
COH2/HDM treatment (Figure 29). Therefore, Treg depletion results in increased
peribronchiolar and perivascular inflammatory cellular infiltration. PAS stained lung
sections were analyzed for mucin production, which stains bright pink when positive.
Saline treated mice were negative for mucin staining as was COH2/HDM treated C57ADAM10B-/- lung sections (Figure 30). Similar to Figure 20, COH2/HDM treated WT
mice had increased mucin compared to COH2/HDM treated C57-ADAM10B-/- (Figure
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30, middle row). Interestingly, mucin staining increased in both WT and C57ADAM10B-/- treated with anti-CD25/HDM (Figure 30, bottom row). Furthermore, the
number or extent of bronchi staining positive for mucin increased as well. Currently, we
are in the process quantifying mucin production.
Lastly, HDM-specific IgE was assessed with and without Treg depletion.
Consistent with previous results (Figure 19C), COH2/HDM treated C57-ADAM10B-/mice produce significantly less HDM-specific IgE compared to COH2/HDM treated WT.
Interestingly, anti-CD25 treatment increased HDM-specific IgE in C57-ADAM10B-/- mice
to WT levels (Figure 28D). HDM-specific IgE levels in anti-CD25 treated WT mice also
trended upward compared to WT treated with COH2. Figure 28D is critically important
for understanding the phenotype of C57-ADAM10B-/- mice. It demonstrates that
increased Tregs in C57-ADAM10B-/- mice plays a central role in reducing antigen
specific Ig production. It is likely, however, that increased Tregs along with other factors
provide a complete explanation for the phenotype. One additional factor perhaps is that
a greater percentage of B220+ B cells are IL-10 producing B10 cells, which are less
adept at producing class switched antibody.
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Figure 28. Treg depletion in C57-ADAM10B-/- prior to HDM challenge increases
AHR, BALF cellularity, eosinophil infiltration, and HDM-specific IgE.
(A) Airway resistance following increasing doses of methacholine. Bar graph (right)
demonstrates airway resistance at 25 mg/mL methacholine dose. (A) Total BALF cells
normalized to 100µL volume. Anti-CD25/HDM treated (black) and COH2/HDM treated
(checkered). (C) BALF cell differential; eosinophils (black), PMN (white), lymphocytes
(horizontal striped), and mononuclear cells (vertical striped). (D) HDM-specific IgE
determined by ELISA. *p<0.05, **p<0.005.
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Figure 29. Treg depletion increases peribronchiolar and perivascular
inflammatory cellular infiltration in WT and C57-ADAM10B-/-.
Representative H&E stained lung sections demonstrating peribronchiolar (thin arrow)
and perivascular (thick arrow) inflammatory cellular infiltration. Note the differences in
the thickness of rings of inflammatory cell as well. All 10x magnification, scale bar 200
µm. Representative of 2 lung sections per mouse and 3 mice per group.
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Figure 30. Anti-CD25 treatment increases mucin in WT and C57-ADAM10B-/airways.
Representative PAS stained lung sections demonstrating the presence of dark pink
staining mucin (arrow). All at 20x magnification, scale bar 100 µm. Representative of 2
lung sections per mouse and 3 mice per group.
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1.5.6 Other unique features of ADAM10B-/- B cells
C57-ADAM10B-/- B cells have other unique properties that may also affect their
ability to effectively produce antibody. Naïve B cells should be CD43 negative and upon
activation CD43 expression increases. When trying to isolate CD43 negative B cells by
magnetic bead isolation (CD43 depletion), significantly fewer B cells were recovered
from C57-ADAM10B-/- compared to WT. This led us to investigate CD43 expression
levels on C57-ADAM10B-/- B cells. Figure 31 demonstrates that naïve B cells isolated
from C57-ADAM10B-/- spleen and lymph node have increased CD43 expression in the
naïve state. Increased B cell activation markers suggests that C57-ADAM10B-/- B cells
are in a pre-activated state and may be refractory to subsequent stimulation. If so, this
finding may help explain reduced antibody production and other B cell defects seen in
these mice.
Furthermore, C57- ADAM10B-/- B cells fail to reconstitute the secondary lymphoid
organs of B cell deficient mice as effectively as WT B cells (Figure 32A and 32B).
C57Bl/6 B cell deficient mice were reconstituted i.v. with WT or C57- ADAM10B-/- B cells
and subsequent B cell reconstitution of secondary lymphoid organs was assessed 2
weeks post immunization. Figure 32 demonstrates that B cell reconstitution of both LN
and spleen was reduced nearly 3 fold in C57- ADAM10B-/-. While the mechanism
underlying this phenomena is still under investigation, some potential options are (1)
C57- ADAM10B-/- B cells simply take longer to reconstitute lymphoid tissues than WT;
(2) Differential signaling or lack of chemokine signaling slows or prevents their
reconstitution; or (3) C57- ADAM10B-/- are pre-activated (Figure 31) and may exhibit a
shorter half-life causing high B cell turnover before our 2 week assessment.
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Figure 31. Increased CD43 expression on C57-ADAM10B-/- B cells.
CD43 expression in naïve, B220+ B cells isolated from LN (left) and spleen (right) of WT
(black) and C57-A10KO (red) mice. Gate represents population staining negative and
low in surface CD43.
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Figure 32. C57-ADAM10B-/-B cells fail to reconstitute secondary lymphoid tissues
as effectively as WT B cells.
Following 2 weeks of reconstitution with either WT (white) or A10KO (black) B cells,
percent B220+ B cells in LN (A) and spleen (B) of B cell deficient mice was determined
by flow cytometry.
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Chapter 6: Discussion
1.6.1 Increased ADAM17 and excessive B cell sTNF production provides the
mechanism for aberrant secondary lymphoid tissue architecture in C57-ADAM10B/-

mice
Chaimowitz et al. noted two key immune system alterations in C57-ADAM10B-/-

mice; however, no mechanism was described [107]. First was that lymph node tissue
architecture is disrupted 14 days post immunization with T-dependent antigen including
aberrant B cell/ T cell localization, reduced GC formation, and reduced FDC network
development [107]. Architecture studies herein, further, describe secondary lymphoid
tissue alterations in naïve lymph nodes from C57-ADAM10B-/- mice as well (Figure 7).
Their naïve lymph nodes exhibited aberrant B cell/ T cell localization, reduced FDC
network development, reduced GC formation, increased HEV size and number, fibrosis,
and increased TNF staining in B cell follicle regions [31]. Furthermore, we demonstrate
herein key phenotypic characteristics of C57Bl/6 ADAM10 deficient B cells including
increased ADAM17 expression and function (Figure 15), which resulted in enhanced
TNF message, surface expression, and soluble production (Figure 14).
Three TNF family cytokines, TNF, LTα, and LTβ, are classically studied in
secondary lymphoid tissue architecture maintenance. While ADAM17 is most notably
studied as the TNF sheddase, one study demonstrated that ADAM17 can cleave
membrane bound LTα1β2 heterotrimer on T cells in vitro and this cleavage is blocked
by the ADAM17 inhibitor, TAPI-1 [100]. These structurally homologous and genetically
linked cytokines have been studied individually and as double deficient mouse models,
in an attempt to tease out the contributions of each to secondary lymphoid tissue
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microarchitecture development and maintenance [187]. LTα deficient mice lack lymph
nodes and Peyer’s patches and exhibit abnormal splenic architecture including loss of
B/T segregation and a complete absence of FDC networks, germinal center formation,
and marginal zone B cells [101,102]. LTα as a soluble homotrimer (LTα3) is also known
to play an integral role in lymphoid organization including B/T segregation by binding to
the TNF receptor, p55TNFR-1, suggesting that blockade of this interaction would result
in a similar phenotype to C57-ADAM10B-/- lymph nodes [103]. LTβ deficient mice,
however, experience more mild disruption as they retain mesenteric and cervical lymph
node development and maintain B/T segregation, FDC networks, and germinal center
formation in spleen [104]. Thus far, no reports have been made about the contribution
of B cell specific LTα or LTβ to secondary lymphoid tissue architecture. More similar to
LTα deficient mice, global TNF knockouts lack FDC networks in B cell follicles and fail to
form germinal centers post immunization [32,188,189]. Furthermore, it is known that
without TNF or its receptor p55TNFR-1, B cell follicles and FDC networks fail to form in
peripheral lymph nodes, Peyer’s patches, and spleen; however, the effects of B cell
TNF overexpression had not been previously reported [32,33]. The role of B cell TNF,
specifically, in architecture maintenance has been elucidated using a B cell mutant
model only capable of expressing mTNF. Without B cell sTNF production, there is loss
of a proper cortico-medullary junction, reduced germinal center formation, impaired FDC
network development, and reduced IgG production against T dependent antigens [34].
While it is known that lack of B cell TNF causes aberrant architecture, this study is the
first to describe that excessive B cell TNF also leads to defects in secondary lymphoid
tissue architecture.
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Because p55TNFR-1 binds both TNF and LTα3, it is reasonable to conclude that
excessive TNF could outcompete LTα3 for binding to this receptor, resulting in noted
defects in B/T segregation.

Furthermore, it has been shown that increased sTNF

contributes to HEV neogenesis [190]. Excessive B cell TNF, therefore, could explain
the induction of increased cortical HEV neogenesis resulting in increased T cell
recruitment via CCL21/CCR7 interactions and ultimate aberrancies in B/T segregation
(Figure 7). Furthermore, Weskamp et al. recently demonstrated that ADAM17 is critical
for neovascularization using a conditional knockout model where ADAM17 was
selectively deleted from endothelial cells and pericytes [191].

Therefore, ADAM17

overexpression by C57-ADAM10B-/- B cells may be directly involved in increased
follicular HEVs (Figure 7).

Furthermore, in a Notch-dependent pathway, ADAM17

overactivation has been implicated in fibroblast activation, excessive collagen formation,
and fibrosis [192]. Increased ADAM17 in C57-ADAM10B-/- B cells could lead to aberrant
Notch signaling and increased fibrosis within the lymph node (Figure 7). Given the profibrotic properties of ADAM17, our result that ADAM17 overcompensates for ADAM10
deficiency must be well-considered prior to attempting ADAM10 therapeutic
neutralization.
There are two key pieces of data furthering the mechanistic contribution of TNF
over other ligands. First, is the recovery of WT architecture in irradiated WT mice
reconstituted with a 50/50 mix of C57-ADAM10B-/- + TNFKO bone marrow (Figure 12F
12G). Compared to high TNF levels noted in WT mice reconstituted with C57ADAM10B-/- bone marrow alone (Figure 12B and 12G) or a 50/50 mix of C57-ADAM10B/-

+ WT CD45.1 (Figure 12E and 12G), those reconstituted with a 50/50 mix of C57-

110

ADAM10B-/- + TNFKO bone marrow produce an appropriate level of TNF considering
ADAM10B-/- B cells make too much and TNFKO B cells make none; thus, further
supporting the mechanistic contribution of TNF. With the combination C57-ADAM10B-/+ TNFKO model, it is important to note that all cells in the TNFKO do not make TNF,
which may contribute to the effect seen. Second, our findings in Balb-ADAM10B-/- B
cells and lymph nodes indicate that Balb-ADAM10B-/- B cells exhibit only a marginal
increase in ADAM17 expression (Figure 15) and activity leading to WT levels of TNF
production, surface expression, and mRNA message levels (Figure 14). This coincided
with maintenance of WT lymph node tissue architecture and normal TNF staining within
B cell follicle regions (Figure 16).
To conclude, this part of our study demonstrates that compensatory changes in
ADAM17 expression and function in the absence of ADAM10 is strain dependent and
more exaggerated in Th1 prone C57Bl/6 mice (Figure 15). This finding has substantial
implications in therapeutic design where specific targeting of one ADAM may lead to
changes in other closely related ADAMs depending on genetic background.
Furthermore, it is important to study the interaction between ADAM10 and ADAM17 on
other cell types as well to further elucidate other potential complications. Lastly, this
part of our study describes the mechanism underling aberrant secondary lymphoid
tissue architecture in C57-ADAM10B-/- LNs. The compensatory increase in B cell
ADAM17 leads to increased production of B cell TNF, which ultimately underlies
architectural aberrancies noted in C57-ADAM10B-/- LNs. Balb-ADAM10B-/- B cells fail to
increase ADAM17 and TNF production and retain WT architecture characteristics. This
finding lends new insight to the discussion regarding how B cell TNF homeostasis is
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critical for secondary lymphoid tissue organization and how a proper B cell
ADAM10/ADAM17 ratio is needed to ultimately control TNF signaling.
1.6.2. Increased B cell ADAM10 and reduced ADAM17 and TNF is predicative of
increased susceptibility to Th2 responsiveness
Compelling evidence, herein, demonstrates that B cell ADAM10, ADAM17, and
TNF are differentially regulated in Th1 and Th2-dominated immune responses and
directly influences host susceptibility to allergy and IgE production. We demonstrate
that Th2 prone mouse strains (Figure 17) and humans (Figure 21, Table 5) exhibit
increased B cell ADAM10 and IgE, while concomitantly having reduced ADAM17 and
TNF (Figure 17 and 21). With regards to mouse strains, we described above that Th
environment is critical for ADAM17 and TNF regulation in the absence of ADAM10 as
Balb-ADAM10B-/- are less adept at increasing ADAM17 and thus, TNF cleavage (Figure
14 and 15) [31].
A critical question is whether the B cell ADAM10 level is strictly determined by T
cell help or is an inherent characteristic of B cells from Th1 or Th2 prone strains. The
answer is both. T cell help as demonstrated by in vitro culture with equal concentrations
of anti-CD40/IL-4 shows that B cell ADAM10 increases in both C57 and Balb WT B cells
following stimulation (Table 4, Figure 17). Thus, T cell help augments ADAM10
expression. Importantly, however, Balb WT B cells exhibit increased ADAM10 in the
naïve state and even more dramatically increased ADAM10 after anti-CD40/IL4
stimulation compared C57-WT B cells (Table 4). This finding indicates an innate
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difference between their B cells that affects their sensitivity to T cell mediated ADAM10
induction.
Next, regulation of ADAM17 and its ligand, TNF, in different Th contexts was
analyzed. C57-WT B cells demonstrated increased ADAM17 in naïve B cells and
increased TNF expression following in vitro stimulation compared to Balb-WT B cells
(Figure 14). These B cell differences in the classic Th1 and Th2-biased strains
extended to other strains of mice as well. For our studies, we used SJL/J and C57Bl/6
as our Th1 prone strains and A/J and Balb/c as our Th2 prone strains (Figure 17).
Furthermore, Th context is critical for understanding the difference in ADAM17 and TNF
regulation following B cell ADAM10 deletion (Figures 14 and 15), as Balb-ADAM10B-/- B
cells fail to increase ADAM17 and TNF production, thus permitting WT architecture
maintenance (Figure 16). Our evidence suggests that regulation of B cell ADAM10 and
ADAM17 is determined by both Th context (e.g. T cell help) and inherent differences in
B cell responsiveness.
We next described how both Th context and B cell ADAM10 level are critical
when determining susceptibility to airway hypersensitivity induction in mice. Our lab
had previously used an OVA-induced airway hypersensitivity model, which showed a
reduction in disease parameters in C57-ADAM10B-/- mice including airway resistance,
OVA- specific IgE, mucus production, and eosinophil infiltration [180]. Using a more
clinically relevant HDM model, herein, we directly compare C57 and Balb ADAM10B-/mice and both experienced significantly less bronchoconstriction, goblet cell metaplasia,
mucus, and HDM-specific IgE production (in Balb/c) compared to their respective WT
strain (Figures 19 and 20). Importantly, however, Balb- ADAM10B-/- mice had lung
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inflammation parameters comparable to WT-C57 mice, while C57-ADAM10B-/- had the
lowest disease induction. Furthermore, while clinically relevant features of human
asthma including antigen-specific IgE, mucus, and airway resistance were clearly
enhanced in an ADAM10 dependent manner, eosinophil infiltration was strain
dependent only as Balb/c mice regardless of ADAM10 level had increased eosinophil
counts compared to C57 WT and C57-ADAM10B-/- mice (Figure 19). This finding does
not detract from the potential use of ADAM10 inhibitor therapy, however, because
blockade of eosinophil infiltration by anti-IL-5 monoclonal antibodies alone failed to
reduce asthma related symptoms in most allergic patients [193,194]. Overall, the data
indicates that B cell ADAM10 plays an important role in this Th2 disease model with the
highest ADAM10 expression indicating worst symptomology. While the mechanism by
which ADAM10 levels influence Th2 disease is unknown, a candidate mechanism could
be that ADAM10-mediated CD23 shedding increases IgE production, thus enhancing
IgE cross-linking and mast cell degranulation [30]. If further validated in a larger human
cohort study, ADAM10 level could serve as a potential indicator of the directionality or
strength of a Th1 or Th2 response, with high ADAM10 level indicating a propensity
toward enhanced Th2 responsiveness with excess IgE production.
Our data in mouse strains was validated by our findings in active allergic rhinitis
patients (Th2 prone) who demonstrated increased B cell ADAM10 and reduced B cell
ADAM17 and TNF production (Figure 21). Furthermore, increasing B cell ADAM10
level correlated with increased antigen-specific IgE production (Table 5). Together this
suggests that B cell ADAM10 screening could effectively stratify allergic from nonallergic patients and potentially for their susceptibility to more severe disease. An
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appropriate, cost-effective means to perform this task is used herein: flow cytometric
analysis of ADAM10 levels on peripheral blood CD19+ B cells obtained from a minimally
invasive venous puncture. Furthermore, while ADAM10 screening could be a critical
diagnostic tool, ADAM10 inhibition therapy is an attractive alternative to other commonly
used therapies as it would inhibit the initial step in the allergic cascade: IgE production.
We demonstrate, herein, that B cell ADAM10 deletion reduces antigen-specific IgE
production (Figure 19). Consequently, ADAM10 inhibitors have the potential to provide
anti-allergic prophylaxis when locally administered (e.g. inhaler) particularly to atopic
patients with high B cell ADAM10.
Allergic patients with increased B cell ADAM10 concomitantly had reduced B cell
ADAM17 and TNF, which could also provide mechanistic insight into their enhanced IgE
production. Increased B cell TNF production, as seen in aging B cells, limits antibody
production, suggesting a potentially protective role of ADAM17 and TNF from induction
of an allergic phenotype [108]. Our findings, overall, suggest that allergy-prone B cells
display an ADAM10hi/ADAM17lo/TNFlo phenotype, with greater risk of atopic
manifestations in Th2-biased environments. Our results are an advance in elucidating
the key role of ADAM10 in allergy pathogenesis, and provide a novel approach to the
diagnosis, prognosis, and treatment of atopic disorders.
1.6.3. C57-ADAM10B-/-mice exhibit decreased antibody production, which may be
explained by an increased percentage of B10 cells and increased Tregs
The second immune system alteration in C57-ADAM10B-/- mice described by
Chaimowitz et al. was a reduction in antigen-specific class switched antibody production
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post immunization with T dependent antigen. Unlike the difference in secondary
lymphoid tissue architecture, both C57 and Balb-ADAM10B-/- mice have reduced antigen
specific antibody production post NP-KLH immunization (Figures 4, 5, and 13).
Therefore, increased B cell TNF production cannot be the mechanism underlying this
alteration because Balb-ADAM10B-/- mice do not exhibit increased TNF. We, therefore,
looked into other possible factors that may affect antibody production including a
regulatory B cell phenotype and Treg influence.
B10 cells are a unique subset of B cells that have only recently been described
[145,146]. B10 cells are IL-10 producing B cells, of which only a subset becomes
antibody-secreting cells [164]. Herein, we demonstrate that following in vitro activation,
30% of C57-ADAM10B-/- B cells become IL-10 expressing B cells compared to only 10%
of WT B cells (Figure 22A), which corresponded to increased soluble IL-10 production
as well (Figure 22B). Furthermore, IL-10 message was increased 6 fold in C57ADAM10B-/- B cells following in vitro stimulation (Figure 22C). While the topic is
controversial, some reports state that B10 cells enhance Treg development and
maintenance [161–163]. Our finding of increased IL-10 in the circulation of C57ADAM10B-/- mice (Figure 22E) further supported a potential induction of Tregs, given
that B cells alone are not thought to make that much IL-10.
Tregs were in fact increased in C57-ADAM10B-/- spleens (Figure 23 and 24).
Candidate mechanisms for this Treg enhancement include increased B cell production
of ICOSL and/or IL-10. ICOS-ICOSL interaction is critical for the development and
persistence of Tregs [113,114]. ADAM17 is known to downregulate membrane-bound
ICOSL and increase soluble ICOSL (sICOSL) production by an indirect mechanism
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[112]. Given that C57-ADAM10B-/- B cells have increased ADAM17, this suggests that
increased sICOSL production may enhance ICOS receptor signaling on T cells, thus
inducing FoxP3 expression in a larger subset of T cells. ICOSL was increased in naïve
C57-ADAM10B-/- B cells and thus there is more to be cleaved following ADAM17
activation (Figure 25). Preliminary data suggested that neutralization of ICOSL in cocultures of CD4+CD25- T cells and C57-ADAM10B-/- B cell supernatants reduced FoxP3
expression compared to treatment with C57-ADAM10B-/- B cell supernatant alone
(Figures 27and 28). Further studies are needed to confirm that neutralization of
ICOSL signaling in vitro inhibits FoxP3 induction in CD4+CD25- cells. While IL-10 is not
thought to induce FoxP3 expression, it is known to be critical for maintaining FoxP3
expression [195]. Therefore, it is likely that increased IL-10 production by C57ADAM10B-/- B cells supports FoxP3 expression, which was increased initially by an
alternate source (e.g. ICOSL). IL-10 neutralization experiments should demonstrate a
reduction, even if slight, in FoxP3 expression following stimulation with WT or C57ADAM10B-/- B cell supernatants. Furthermore, inhibition of both ICOSL and IL-10
together should cause the largest suppression of FoxP3 induction in CD4+CD25-/B cell
supernatant co-cultures.
While studies in Balb-ADAM10B-/- still need to be performed, increased Tregs in
C57-ADAM10B-/- mice contributed to decreased class-switched antibody production and
reduced lung inflammation parameters following HDM challenge. Treg depletion in vivo
led to enhanced HDM-specific IgE production in both WT and C57-ADAM10B-/- mice as
well as increased AHR, BALF cellularity, inflammatory cellular infiltration in airways, and
mucus (Figure 28, 29, and 30). Therefore, Tregs do play a mechanistic role in limiting
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class-switched antibody production and lung inflammation in C57-ADAM10B-/- mice. To
validate our findings as a Treg-specific phenomenon, we must still confirm Treg
depletion by flow cytometry. In Setiady et al. anti-CD25 treatment decreased
CD25+FoxP3+ cells from 6.5% to 0.7%, although FoxP3+ cells only decreased from
3.3% to 2.3% [186]. Furthermore, control Rat IgG1 treatment failed to reduce
CD25+FoxP3+ cells from WT levels [186]. We expect to demonstrate similar results.
Furthermore, our findings herein may further the understanding of B10 cells
including their relationship to Tregs and other, un-reported surface markers. Our data
suggests that ICOSL and CD43 may be potential markers of B10 cells. To prove this
point, co-staining with B220, IL-10, and ICOSL or CD43 is needed to show if IL-10
producing B cells specifically upregulate these markers compared to non-IL-10
producing B cells.
Lastly, the overarching goal of section 1 was to define the immune system
alterations in B cell specific ADAM10 deficient mice and determine how differential
ADAM10 levels affects Th2 disease. Ultimately, we aimed to determine if ADAM10
inhibitor therapy would be beneficial in treating allergic diseases and if so, by what
potential mechanism. Previously, we mentioned that ADAM10 inhibitor therapy for Th2
disease was a unique way to regulate IgE production. Our recent findings suggest that
a potential mechanism by which ADAM10 inhibitors may reduce IgE is through
enhancement of Treg cells downstream of enhanced B cell ICOSL or IL-10 production.
It is important to note that ADAM10 inhibitor therapy, however, would not be B cell
specific and could cause off-target effects. An i.v administered dual ADAM10/17
inhibitor has been evaluated in human clinical trials for its anti-neoplastic effects and
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was found to be well tolerated [196]. While it lacked efficacy in blocking tumor growth,
our data suggests that locally administered ADAM10 inhibitor therapy (e.g. inhaler) to
the airway may be preventative against important disease parameters such as
bronchoconstriction and mucus production and should be further explored.
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Section 2: Impaired immunological synapse in sperm associated antigen 6
(SPAG6) deficient mice
Chapter 1: Introduction to SPAG6 and its role in microtubule rearrangement
2.1.1 SPAG6
Mammalian sperm associated antigen 6 (SPAG6), or its orthologue, PF16
protein, from Chlamydomonas reinhardtii, is classically known as a component of the
central apparatus of the “9+2” axoneme, which consists of a central pair of microtubules
(C1 and C2) surrounded by nine outer microtubule doublets with associated dynein
arms [175,197–199]. Mutagenesis of Chlamydomonas PF16 results in flagellar
paralysis and disturbance of C1 central microtubule stability revealing its central role in
flagellar stability and motility [199]. In mammals, SPAG6 is widely expressed, mainly in
tissues with cilia-bearing cells including lung, nervous system, inner ear, bone marrow,
and particularly, testicular germ cells where SPAG6 resides in the sperm flagella
[197,200]. Many of the noted abnormalities associated with SPAG6 deficiency are
related to dysfunctional ciliary or flagellar appendages in ciliated cells and tissues. In
humans, SPAG6 in the sperm tail is targeted by a class of anti-sperm autoantibodies
associated with immune-mediated infertility in males [200]. Global SPAG6-deficient
mice (Spag6KO) exhibit significant defects including a high percentage of neonatal
deaths, hydrocephalus, and infertility in surviving male mice [198]. They also experience
a significant reduction in axoneme numbers and the two central microtubules exhibit a
random orientation compared to WT mice [201]. Furthermore, Spag6KO tracheal
epithelial cells lose their polarized morphology and polarized distribution of mucin; and
these phenotypes appear to be related to a disrupted microtubule system [201]. In
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addition, Spag6KO mice develop otitis media more readily than WT given abnormalities
in the ciliated columnar epithelium in the middle ear and Eustachian tube [202]. While
these examples demonstrate the importance of SPAG6 in ciliated tissues, the role of
SPAG6 in cells lacking classic cilia and/or flagella, such as lymphocytes or other
immune cells, remains unreported. Another protein critical for ciliogenesis, IFT20, has
been shown to be important for microtubule organization and T cell receptor (TCR)
recycling at the immunological synapse [203,204]. Therefore, given the contribution of
SPAG6 protein to microtubule organization, and the critical role of microtubule
organization in cognate immune cell interaction, we sought to analyze the role of
SPAG6 in the formation of the immunological synapse as well as the impact of SPAG6
deficiency on the immune response.
2.1.2 SPAG6 and its role in the MTOC
The microtubule organizing center (MTOC) is a subcellular apparatus that
functions to form and organize microtubules, which in eukaryotic somatic cells is the
centrosome, composed of two orthogonally arranged centrioles (mother centriole and
daughter centriole) [205,206]. During an immune response, upon cognate recognition
between an antigen presenting cell and effector cell, reorientation of the centrosome,
actin, the Golgi, and secretory vesicles occurs in the effector cell at the immunological
synapse, allowing receptor/ligand interactions and targeted release of cytokines [207].
Furthermore, during targeted killing by an effector cell, the same reorientation occurs
with docking of the centrosome at the synapse membrane of the effector cell, effectively
creating the synaptic cleft by which cytolytic enzymes are released for targeted
destruction [205,208]. While SPAG6 is known to be a microtubule-binding protein [197]
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and co-localizes with polymerized microtubules [209], we demonstrate, herein, the
expression of SPAG6 protein in primary and secondary lymphoid tissues, its association
with the centrosome, and the lack of centrosome polarization and actin clearance at the
synaptic cleft of SPAG6 deficient mice. In addition, we show that these synaptic
malformations are associated with reduced CTL cytotoxicity, diminished follicular CD4 T
cell retention in germinal centers, defective germinal center reactions, low production of
class-switched antibodies, and expansion of the B1 B cell subset.

122

Chapter 2: Materials and Methods
2.2.1 Mice
Mice were housed in the Virginia Commonwealth University mouse vivarium in
accordance with NIH guidelines. All animal care and experimental protocols were
approved by IACUC. Spag6KO mice were generated as previously described [198] and
compared to WT littermate controls. C57/SV129 WT male mice age 6-8 weeks were
used for reconstitution.
2.2.2 Bone Marrow Reconstitution
C57/SV129 WT were pretreated with 100 mg/L enrofloxacin for 5 days prior to
irradiation. C57/SV129 WT were anesthetized using 80 mg/kg ketamine and 8 mg/kg
xylazine in PBS and given two doses of 550 cGy irradiation, with a 2-h rest period, using
a MDS Nordion Gammacell 40 research irradiator with a [137Cs] source. Bone marrow
cells were isolated as previously described [169] (see section 1.2.10) and 5 million cells
i.v. injected into irradiated WT. After 6 weeks, mice were footpad and i.p immunized
with 10 µg 4-hydroxy-3-nitrophenylacetyl coupled to keyhole limpet hemocyanin at a
ratio of 27:1 (Bioresearch Technologies) in 4 mg alum. Mice were bled at day 7 and
organs harvested at day 14.
2.2.3 Reagents and T cell culture
Spleen was crushed, filtered, RBCs lysed with ACK Lysing Buffer (Quality Biological),
and cytotoxic T cells isolated from splenocytes by PE-positive selection using CD8-PE
(Biolegend) and EasySep kit (Stemcell Technologies). T cells were grown in complete
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RPMI [31] with 100 Units/mL IL-2 (Peprotech) on overnight anti-CD3ε (1µg/mL,
Biolegend) treated plates with anti-CD28 (2µg/mL, Biolegend) and supernatants
collected for IFN-y ELISA (eBioscience) after 72 h of growth. Proliferation was
assessed after 72 h with a 24-h pulse of [3H] thymidine, 1µCi/well (Perkin Elmer). using
Filtermate cell harvester onto UniFilter-96 GF/C microplates and analyzed by TopCount
Plate Counter (Perkin Elmer).
2.2.4 ELISA
NP-specific antibody
NP-specific IgM and IgG1 was determined by NP-specific ELISA using NP-14–BSA (15
µg/ml; Biosearch Technologies) as previously described in section 1.2.6.
IFNy
Soluble IFN-y from T cell supernatants was determined by mouse quantitative ELISA kit
(88-7314-77, eBioscience) according to manufacturer’s protocol.
2.2.5 Flow cytometry
Single cell suspension of splenocytes, lymph node, and peritoneal lavage cells were
incubated with Fc blocking reagent (10 µg anti-mouse unlabeled CD16/32 (2.4G2));
stained with B220-APC or PeCy5, CD3-PE or PECy7, CD11b-FITC, or GL7-FITC
(Biolegend), washed, examined on a BD Canto Flow analyzer, and data analyzed with
FCS Express, v. 4.
2.2.6 Cytotoxic assay
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CD8+ T cells effector cells were isolated from spleen using EasySep mouse PE
selection Kit (Stemcell Technologies) with CD8-PE (Biolegend). CD8 T cell purity was
verified (95-98%) and cultured with platebound anti-CD3ε and anti-CD28 as described
above in T cell media for 2 days and then seeded into fresh media daily and used 6
days later. P815 (ATCC) target cells were grown in complete RPMI. Cytotox 96 NonRadioactive Cytotoxicity Assay (Promega) was used to first determine P815 optimal cell
concentration (1.2 x 105cells/mL) and then cytotoxicity assay was performed in
quadruplicate.
2.2.7 CTL induction and slide set up for synapse staining
Balb/c WT spleen was collected, crushed, RBC lysed, resuspended to 107/mL,
and irradiated at 3000rad. Cells were then counted, washed in T cells media (RPMI
supplemented with 10% FBS, 50µM β-mercaptoethanol, L-glutamine, sodium pyruvate,
and 50U/mL penicillin and streptomycin), resuspended to 1.25x106/mL, and 1mL of
Balb/c stimulator cells cultured with 1mL (at 1.25x106/mL) of WT or Spag6KO responder
cells for 5 days. Live cells were collected, washed, and resuspended to 1x106/mL in IL2 (100U/mL, Peprotech) supplemented T cell media. Cells were cultured 5 days and
seeded into fresh IL-2 supplemented media daily.
Chamber slides (Thermo Scientific, no. 154534) were coated with ICAM-Fc
(1µg/mL) in sterile BBS overnight at 4°C. WT or Spag6 (three per group) CTLs and
P815 were resuspended to 4x106/mL. 125µL of CTL and P815 were incubated
separately at 37°C for 5 minutes, mixed, incubated again for 5 minutes, then diluted to
1x106/mL in warm T cell media. Cells were incubated on slides for 10 minutes at 37°C,
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media removed, ice cold 100% methanol added, incubated for at least 5 minutes,
methanol removed, and slides dried for 30 minutes at 4°C. Slides were set up as CTL
alone, P815 alone, CTL+ P815, or PBS only.
2.2.8 Immunohisto-, cyto-chemistry, and confocal microscopy
Ten um OCT-embedded frozen sections of WT and Spag6KO lymph nodes were fixed
in ice-cold acetone for 10 mins then left to air-dry. The sections were re-hydrated and
blocked with 2% horse serum, then labelled with 10 µg/ml FITC-conjugated T- and BCell Activation Antigen (clone GL7, BD Biosciences 553666), PE-conjugated Rat AntiMouse CD4 (clone GK1.5, southern biotech 1540-09L ), and Alexa Flour 647conjugated rat anti mouse CD21/35 (clone 7E9, Invitrogen Molecular Probes,
RMCD213521) for 45 mins. Sections were thoroughly washed, mounted with anti-fade
mounting medium, Vectashield (Vector Laboratories), and cover-slipped. The sections
were examined with Leica TCS-SP2 AOBS confocal laser scanning microscope fitted
with an oil plan-apochromat ×40 objective. Three lasers were used: Argon (488 nm) for
FITC, HeNe (543 nm) for PE, and HeNe (633 nm) for Alexa Flour 647 (shown as
pseudo-color blue). Parameters were adjusted to scan at 1024 × 1024 pixel density and
8-bit pixel depth. Emissions were recorded in three separate channels, and digital
images were captured and processed with Leica Confocal and LCS Lite software. The
number, size and CD4 content of GCs in the LNs of WT and Spag6KO mice were
counted and measured, and the average was presented + SD.
For immuno-cyto-chemistry, WT or Spag6KO splenocytes were co-cultured with
irradiated Balb/c splenocytes for 5 days, remaining live cells seeded into fresh IL-2
supplemented cRPMI for 3 days, and then allogeneic CTLs were cultured briefly with
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P815 target cells. Cells were transferred to pre-coated (ICAM-Fc, 1µg/mL, R&D) Nunc
chamber slides (Thermo Scientific) and fixed in cold methanol, left to dry then blocked
with 2% horse serum. The cells were labeled with rabbit anti α-actin antibody (SigmaAldrich A2066-.2ML) or mouse anti gamma-tubulin (clone GTU-88, Sigma-Aldrich
T6557-.2ML) for 45 mins then washed. Alexa Flour 488-conjugated Fab’2 fragment
donkey anti-Rabbit IgG (H+L) (Jackson Immuno-Research 711-546-152) or anti Mouse
IgG (H+L) (Jackson Immuno-Research 715-546-150) [with minimal cross reactivity to
horse, mouse, rabbit, goat, human and rat proteins] secondary antibodies were then
added together with rat anti-mouse CD8a-PE (southern Biotech, 1550-09L) and
NucRed 647 nuclear stain (Invitrogen, R37113). After 45 mins, the cells were thoroughly
washed, mounted with anti-fade mounting medium, Vectashield (Vector Laboratories),
and cover-slipped. The cells were examined with Zeiss Laser Scanning Microscope
LSM 710 fitted with an oil plan-apochromat ×40, x63, and x100 objectives. Three lasers
were used: Argon (488 nm) for FITC, HeNe (543 nm) for PE, and HeNe (633 nm) for
NucRed 647 (shown as pseudo-color blue). Parameters were adjusted to scan at 1024
× 1024 pixel density and 8-bit pixel depth. Emissions were recorded in three separate
channels, and digital images were captured. Z stacks running through the
immunological synapse with 0.40 µm step-size were generated and re-structured into 3dimensional snap shots and movies using Zeiss Zen 2012 (Blue Edition) software.
2.2.9 Centrosome staining
HEK293-T cells were transfected with SPAG6/pcDNA3 plasmid and 48 hours post
transfection cells were permeabilized with 1% Triton X-100, blocked, incubated
overnight at 4°C with a polyclonal anti-SPAG6 and monoclonal anti-γ-tubulin, washed,
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and incubated for 1 h at room temperature with Alexa 488-anti-mouse IgG (Jackson
Immuno Research Laboratories) and Cy3-anti-rabbit IgG (Jackson ImmunoResearch
Laboratories). Finally slides were washed and sealed using VectaMount with 4', 6diamidino-2-phenylindole (DAPI) (Vector Laboratories). Images were taken by confocal
laser-scanning microscopy (Leica TCS-SP2 AOBS).
2.2.10 RT-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen), reverse transcribed using
RETROscript® (Ambion, AM1710), and PCR performed to examine Spag6 mRNA
expression compared to Gapdh control . The primer set used in our previous study was
applied [210].
2.2.11 Statistical analysis
Normal distribution of data was determined using Shapiro-Wilk normality test in
SigmaPlot 12.5. The p values were calculated using unpaired two-tailed Student t tests
in GraphPad Prism. Error bars represent the SEM between samples. A p value <0.05 is
considered significant.
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Chapter 3: Results and Discussion
2.3.1 SPAG6 is expressed in primary and secondary lymphoid tissues and colocalizes with the centrosome
The expression and role of SPAG6 in immune system development and adaptive
functions is unknown. While the murine immune system fails to mature until about six
weeks of age, the majority of Spag6KO mice survive less than three weeks due to
numerous developmental defects. Therefore, we first confirmed expression of Spag6 in
various immune cells and tissues of adult WT mice including spleen, thymus, bone
marrow, lymph node and naïve T cells by RT-PCR (Figure 33). In order to study
SPAG6 loss in a mature immune system, adult WT mice were irradiated and
reconstituted with 7-14 day old WT or Spag6KO bone marrow. SPAG6 is known to be
critical for ciliogenesis and microtubule-based motility [201]; and despite the fact that
lymphocytes do not have cilia, their engagement with antigen presenting cells and
target cells involves extensive remodeling of cytoskeletal and motor proteins. De la
Roche et al. proposed that the T cell immunological synapse at the interface between T
cells and antigen presenting / target cells is a “surrogate cilium” because it utilizes the
same machinery as ciliogenesis including the nucleation of microtubules at the MTOC
or centrosome [207,211]. De la Roche et al. also described how Hedgehog signaling,
originally known for its role in primary cilia formation, is also critical for CTL function and
immunological synapse formation [207]. Consequently, we sought to determine if
SPAG6 is present in the MTOC or centrosome and, if so, could SPAG6 be required for
proper immunological synapse formation and function. We previously reported that
SPAG6 decorated and appeared to organize the microtubules in transfected CHO cells
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[209], however, whether SPAG6 protein is a structural component of the MTOC or
centrosome is not known. To explore the SPAG6-centrosome association, HEK293
cells were transfected with SPAG6/pcDNA3 plasmid and then the cells were double
labeled with a polyclonal antibody against SPAG6 and a monoclonal antibody against γtubulin, a centrosome component. As shown in Figure 34, SPAG6 co-localized with γtubulin indicating that SPAG6 protein is structurally associated with the
MTOC/centrosome apparatus.
2.3.2 SPAG6 is required for centrosome polarization and actin clearance at the
immunological synapse
Given that SPAG6 is structurally associated with the centrosome (Figure 34),
and the centrosome is crucially involved in synapse organization, we predicted that
SPAG6 plays a critical role in immunological synapse formation. Two hallmarks of
adequate synapse formation are centrosome polarization to the synapse and actin
clearance from the synapse [207]. At the central supra-molecular activation cluster of
the immunological synapse, the centrosome moves to and contacts with the plasma
membrane, whereas actin is cleared away from the synapse. It has been proposed that
centrosome polarization might be driven by the reorganization of the actin cytoskeleton,
clearing the plus ends of microtubules from the area of contact and pulling the
centrosome towards the plasma membrane [212]. To analyze the role of SPAG6 in
synapse formation, allogeneic CTLs were cultured briefly with P815 target cells, then
labeled for α-actin and γ-tubulin to visualize the synaptic cleft at the interface between
CTLs and their targets. Figure 35 A, C demonstrates that SPAG6 is required for actin
clearance at the synapse as lack of SPAG6 in Spag6KO CD8 T cells was associated
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with inefficient actin clearance and persistence of actin staining at the synapse. On the
other hand, WT CD8 T cells efficiently cleared actin at the synapse and labeling showed
an actin ring distal to the synapse. Movies constructed from z stacks passing through
the whole depth of the synapses confirmed lack of actin clearance in Spag6KO mice
and efficient regression in the WT mice (data not shown). Actin reorganization is
thought to play a role in centrosome polarization [212], consequently, lack of SPAG6
also resulted in improper polarization of the centrosome and lack of positioning at the
synapse (Figure 35 B, C). Specifically, in WT CTL cells, centrosome docking at the
synapse occurred in 50% of CTL/target cell synapses with only 10% positioned distal to
the synapse; whereas, Spag6KO CTLs exhibited centrosome docking in only 30% of
synapses (Figure 35C). Furthermore, the majority of centrosomes were docked or
proximal to the synapse in WT CD8 T cells compared to Spag6KO CD8 T cells where
the majority were distal or proximal to the synapse, with fewer docked (Figure 35C).
2.3.3 Reduced T cell cytotoxicity in Spag6KO
Thus far, we have determined that SPAG6 is expressed in primary and
secondary lymphoid tissues (Figure 33), co-localizes with the centrosome (Figure 34),
and its deficiency is associated with defective centrosome polarization and actin
clearance (Figure 35) suggesting that these structural abnormalities will obstruct proper
functional communication at the synapse site, which can be assessed by analyzing
cytotoxic T cell (CTL) killing of target cells and T cell-dependent class-switched antibody
production in WT and Spag6KO mice.
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CTLs destroy target cells following T cell receptor activation through release of
secretory lysosomes at the immunological synapse. T cell receptor activation triggers
migration of the MTOC to the contact site, causing the generated microtubule network
to polarize towards the target [208]. Secretory lysosomes then travel in a minus end
direction toward the MTOC [208] followed by transient fusion of the centrosome with the
plasma membrane to mediate secretion into the synapse [212]. Given the presence of
SPAG6 in the centrosome, we reasoned that in the absence of SPAG6, reduced CTLinduced cytotoxicity would occur. We performed an allogeneic cytotoxic T cell assay
and demonstrated that Spag6KO T cells had significantly reduced capacity to induce
P815 cell death compared to WT CD8 T cells (Figure 36A). Furthermore, stimulated
Spag6KO CD8 T cells had reduced secretion of soluble IFNγ (Figure 36B). These
findings are not due to reduced T cell number (Figure 36C) or their ability to proliferate
(Figure 36D). In fact, Spag6KO CD8 T cells cultured with anti-CD3/CD28 exhibit
enhanced proliferation compared to WT CD8 T cells (Figure 36D), suggesting an even
greater reduction in IFNγ secretion per cell than is suggested in Figure 36B.
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Figure 33. SPAG6 expression in lymphoid cells and tissues.
Spag6 expression in adult WT mice compared to testis (positive control) and negative
control (water). Spag6 is expressed in primary (thymus, bone marrow) and secondary
(spleen, lymph node) lymphoid tissues and T cells.
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Figure 34. Presence of SPAG6 protein in the centrosome.
HEK293 cells were transfected with SPAG6/pcDNA3 expressing plasmid, and the cells
were stained for DAPI (blue), SPAG6 (red) and γ-tubulin (green), a component of
centrosome. Co-localization of SPAG6 and γ-tubulin is indicated by white arrows.
Figure courtesy of Dr. Zhibing Zhang.
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Figure 35. Defective actin clearance and centrosome polarization at the
immunological synapse in Spag6KO mice.
(A, B) The immunological synapse between WT or Spag6KO CD8+ CTLs (red) and
P815 target cells was stained for (A) α-actin (green, white arrows, upper panel) or (B) γtubulin (green dots, white arrows, lower panel). (C) Quantification of actin clearance
(left) and centrosome (γ-tubulin) polarization and docking distance from the synapse in
WT and Spag6KO CD8+ cells shown. P values shown.
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Figure 35. Defective actin clearance and centrosome polarization at the
immunological synapse in Spag6KO mice.
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Figure 36. Reduced CTL function in Spag6KO mice.
(A) Allogeneic cytotoxicity assay with decreasing ratios of WT (solid) or Spag6KO
(dashed) CD8+ T cells to P815 target cells; (B) Soluble IFNγ production by WT or
Spag6KO CD8+ T cells (C) CD3+ T cell percentage of total splenocytes; gated from
live singlets. (D) WT or Spag6KO (KO) CD8+ T cell proliferation in media alone (white)
or with CD3/CD28 stimulation (stripes). N=3-7 per group; **p<0.005, ***p<0.0005.
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2.3.4 WT mice reconstituted with SPAG6 deficient bone marrow exhibit impaired
GC formation, diminished follicular CD4 T cells, reduced class-switched antibody
production, and expansion of B1 B cells
Establishment of a proper immunological synapse is required for optimal
antibody production as well. A series of synapses is generated to mount an effective
humoral immune response. First, a synapse between cognate antigen-specific B and T
cells occurs at the B/T border to trigger downstream GC formation.

Furthermore,

synapse formation and signaling between B cells and Tfh cells is required for class
switch recombination and affinity maturation [213]. Moreover, BCR engagement with
FDC-retained antigens is critical for GC persistence and selection of high affinity B cell
clones [214]. We, therefore, hypothesized that Spag6KO mice, who have a comparable
number of B cells to WT (data not shown), would exhibit impaired GC formation and
reduced class-switched antibody production post immunization with T cell-dependent
antigens.

Following immunization with the T cell-dependent NP-KLH antigen, the

germinal center reactions and CD4+ T cells in the draining LNs were assessed in WT or
Spag6KO reconstituted mice. Following 14 days of immunization, the number and size
of GCs in the follicle were significantly reduced in Spag6KO (Figure 37A).
Furthermore, the number of GC CD4+ T cells were significantly diminished, suggesting
reduced migration of Tfh cells to the GC perhaps due to lack of initial
signaling/interaction with the B cell, or due to impaired retention in the GC due to lack of
effective GCB cell/T cell synapse (Figure 37A).

In fact, stable GC-B cell/T cell

interaction is critical for selection of antigen-specific B cells, B cell activation and plasma
cell differentiation, and this interaction is associated with reduction in both GCB and Tfh

138

cell velocities, along with an increase in the duration and size of the T-B contacts
[84,215–218].
The reduction in GC formation and CD4+ T cells in Spag6KO mice
corresponded with significantly reduced NP-specific IgG1 production on day 14 (Figure
37B, right). While NP-specific IgM and IgG1 levels were comparable at day 7 post
immunization (data not shown), NP-specific IgM is increased in Spag6KO serum at day
14 (Figure 37B, left). This result could be attributed to increased extrafollicular
antibody production in Spag6KO B2 cells or perhaps due to the increase in peritoneal
B1 B cells (Figure 37C). B1 B cells are innate, self-renewing, long lived B cells, which
typically reside in the peritoneal and pleural cavities as well as spleen [219]. They fail to
enter germinal centers, are thought to make natural antibodies, and do not require
cognate T cell interaction for IgM production [219]. Our noted increase in B1 B cells in
the absence of SPAG6 suggests that SPAG6 is involved in attenuating the B1 response
and may be an interesting target for limiting autoimmune reactions, as increased B1 B
cells are related to predisposition to autoimmunity [220,221].
In conclusion, while classically studied in ciliary and flagellar motility, SPAG6 is
expressed in primary and secondary lymphoid tissues and its role in immune system
development and function stems from its critical role in proper immunological synapse
formation. We provide novel and substantial evidence that SPAG6 is present in the
centrosome and is required for optimal centrosome polarization and actin clearance
during synapse formation. SPAG6 deficiency is associated with inadequate synapse
formation manifested by significant functional consequences including reduced CD8
cytotoxicity, CD8 T cell IFNγ secretion, GC formation, GC CD4+ T cell retention, and
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class-switched antibody production. These structural and functional abnormalities were
associated with an increase in B1 B cell subset numbers. Finally, original data
presented in this study paves the way for new investigations on the role of SPAG6 in
synapse-dependent immunological interactions and the impact of SPAG6 targeting by
autoantibodies in immune infertility on cellular and humoral immune responses.
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Figure 37. Defective humoral immune response in SPAG6KO mice.
(A) Reduced GC formation and GC CD4+ T cells in draining LN (day 14) of WT (left)
and Spag6KO (right) reconstituted mice. GCs (GL7+, green), FDCs (CD21+, blue), and
CD4 T cells (red) are shown. On the top, triple overlay (left) and separate channel
recordings (right) shown for WT and Spag6KO. Below, GC morphometric analysis of at
least 6 sections per group showed reduced number and size of GCs and CD4+ T cells
per GC in Spag6KO. Day 14 NP
NP-KLH specific (B, left) IgM and (B, right) IgG1 levels in
sera. (C) Percentage of peritoneal B1 B cells (B220+CD11b+) collected at day 14. N=9
per group, 3 independent
ndent experiments. *p<0.05, **p<0.005.
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